



Go Green, Go Online!  
**JDDonline.com**

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

## 2010 SUBJECT INDEX

Letters after article titles refer to the following: **BC** = Brief Communication; **CR** = Case Reports; **CTR** = Clinical Trial Review; **FO** = Focus On; **IC** = Invited Commentary; **LCN** = Laser and Cosmetic News; **LR** = Literature Review; **NND** = No-Nonsense Dermoscopy; **NVR** = News, Views, and Reviews; **PP** = Pipeline Previews; **RR** = Resident Rounds; **SCF Update** = Skin Cancer Foundation Update; **SP** = Schools of Pharmacology; **WU** = Washington Update

- A**
- Abatacept**, safety and efficacy for chronic urticaria after inadequate response to antihistamine therapy (CTR), 86, 1159
- Abobotulinumtoxin A**. See also Botulinum toxin retrospective review of 500 patients treated with, 1081
- Abscesses**, cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439
- ABT-874**. See Briakinumab
- AC-820 (nalfurafine HCl)**, safety and efficacy in subjects on hemodialysis with uremic pruritus (CTR), 82
- Acanthosis nigricans**, retinoids for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151
- AccuView DV-5 Multi Imaging System** (PP), 418
- Acetyl hexapeptide-8 (AH8)**, in treatment of blepharospasm (CTR), 82
- Acitretin**, systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients and, 753
- Acne keloidalis nuchae**, Nd:YAG laser for (CTR), 577
- Acne vulgaris**
- AADA calls for FDA to address Internet sales of isotretinoin and (PP), 282
- acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727
- anti-inflammatory effects of topical dapsone for, 667
- antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for, 131
- apremilast for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
- avoiding antimicrobial resistance in treatment of, 519
- benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80
- body image disturbance in patients with (RR), 725
- comparative study of tolerability of two combination therapies for (CTR), 187, 425
- comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229
- correction of atrophic acne scars with Artefil<sup>®</sup>, 1062
- current guide to laser and light-based therapies for, 614
- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for, 33
- development of antimicrobial resistance due to antibiotic treatment of, 655
- drug-associated acne and acneiform eruptions, 627
- efficacy and safety of CD07223 gel in subjects with (CTR), 1446
- efficacy and safety of doxycycline and minocycline for, 1407
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel in adolescents, 1395
- efficacy and safety of Visonac PDT for (CTR), 1155, 1289, 1446
- efficacy of benzoyl peroxide emollient foam and benzoyl peroxide wash for acne on the back, 622
- Epiduo<sup>®</sup> pediatric acne study (CTR), 1155
- Galderma receives approval for Differin<sup>®</sup> (adapalene) lotion 0.1% for (PP), 723
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel for, 998
- tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for, 805
- optimizing therapy with unique vehicles, s53 (May)
- PDT with MAL cream in patients with skin type V or VI with (CTR), 187, 425
- PDT with MAL without occlusion for, 1347
- in pregnancy (NVR), 1297
- properties of benzoyl peroxide and, 482
- psychosocial sequelae related to, s50 (May)
- two randomized clinical studies of adapalene lotion for, 639
- safety and efficacy of IDP-107 in patients with (CTR), 1446
- safety and efficacy of tazarotene cream and adapalene gel in, 549
- safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446
- safety of dapsone in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
- single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341
- spironolactone and metformin in treatment of (NVR), 569
- topical tretinoin gel and acne in preadolescents (PP), 1033
- treatment of facial atrophic scars with Esthé<sup>lis</sup>, 1507
- we are making progress with acne and rosacea (editorial), 603
- Acral lentiginous melanoma**, unilateral lichen planus pigmentosus mimicking (CR), 841
- Acrylic hydrogen suspended in hyaluronic acid**, histopathologic identification of dermal filler agents, 1072
- Actinic cheilitis**, PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- Actinic keratoses (AK)**
- ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82
- development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022
- efficacy and safety study of 3.75% imiquimod cream following cryosurgery for, 1101
- etiology, epidemiology and clinical presentation, 1125
- FDA 510(k) clearance of Fraxel re:store Dual Laser for (PP), 1552
- FDA approves Zyclara<sup>™</sup> for (PP), 723
- past, present, and future, s45 (May)
- Perrigo announces FDA approval for imiquimod cream for (PP), 1552
- reduced number of AK with DNA repair enzyme creams, 1519
- topical perillyl alcohol in treating patients with sun damaged skin and AK (CTR), 82
- utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Acupuncture**, localized argyria secondary to (CR), 1019
- Acute cutaneous necrosis**, drug therapy for, 341
- Adalimumab**
- how and when to use biologics in psoriasis, s106 (August)
- use of biologic agents in pediatric psoriasis and, 975
- Adapalene**
- comparative study of tolerability of two combination therapies for acne (CTR), 187, 425

- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
- Epiduo® pediatric acne study (CTR), 1155
- Galderma receives approval for Differin® (adapalene) lotion 0.1% (PP), 723
- generic approval of adapalene cream 0.1% (PP), 1160
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel, 998
- properties of benzoyl peroxide, combined with, 482
- randomized clinical studies of adapalene lotion for acne, 639
- safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
- trends in use for acne vulgaris, 519
- AEB071**, dose finding study assessing psoriasis area and severity index in patients with plaque psoriasis (CTR), 285
- Afamelanotide**, Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial (PP), 723
- Aging skin**. See Cutaneous aging
- AIN457**, regimen finding study in psoriasis (CTR), 285
- Albaconazole**, study of effects of increasing doses of drug for nail fungus (CTR), 187, 425
- Alcoholics**, treatment of psoriasis in (CR), 405
- Alefacept**  
how and when to use biologics in psoriasis and, s106 (August)  
treatment of psoriasis for up to one year, 1491  
use of biologic agents in pediatric psoriasis and, 975
- Alemtuzumab**, followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883
- Allium cepa, medical and surgical management of keloids and, 1249
- Aloe vera**, botanical approaches to alopecia and, 537
- Alopecia**  
botanical approaches to, 537  
hair growth in patients with alopecia areata totalis after treatment with simvastatin and ezetimibe (CR), 62  
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446  
minoxidil for female pattern hair loss (CTR), 1446  
new study implicates autoimmune mechanisms in alopecia areata (PP), 1160  
pathogenesis, genetics and medical treatment of patterned hair loss, 1412  
safety and pharmacokinetics of new formulation of bimatoprost in (CTR), 1446  
spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577  
treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82  
treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Altanax®**. See Retapamulin
- AMG 157**, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- Amineptine**, drug-associated acne and acneiform eruptions, 627
- Aminolevulinic acid (ALA)**  
ALA-PDT for cutaneous pseudolymphoma (CR), 688  
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82  
comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229  
PDT using ALA in treating patients with skin cancer (CTR), 82  
PDT with MAL cream in patients with skin type V or VI with acne (CTR), 187, 425
- Ammonium lactate**, efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035
- Anakinra**, for atopic dermatitis (CTR), 1035, 1155, 1446
- Androgens and anabolic-androgenic drugs**, drug-associated acne and acneiform eruptions, 627
- Anesthetics, topical**  
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097  
FDA approves Juvéderm® XC with lidocaine (PP), 418  
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577  
safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500
- Angioedema** (NVR), 1545  
hereditary, FDA approval of ecallantide for (PP), 572
- Angioimmunoblastic T-cell lymphoma**, primary cutaneous (CR), 851
- Angiosarcoma**  
bevacizumab for (CTR), 285  
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and (CTR), 285
- Animal models**, ustekinumab effects on primate/human antigen-recall and humoral immune response functions, 677
- Anisotriazine**, sunscreen update: controversies, what's safe, what's next (NVR), 1451
- Annular leukocytoclastic vasculitis**, sorafenib-associated (CR), 697
- Anogenital warts**, Helix BioPharma and topical interferon alpha-2b for (PP), 723
- Anorexia nervosa**, dermatologic indicators of (NVR), 412
- Antiepileptic drugs**, postpubertal eruptive syringoma triggered with (CR), 707
- Antifungal drugs**  
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525  
comparison of SUBA™-itraconazole with SPO-RANOX® for onychomycosis (CTR), 187, 285, 425  
cutaneous fixed drug eruption to fluconazole (CR), 1025  
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155  
efficacy of itraconazole in BCC (CTR), 883, 1035  
fluconazole-associated Stevens-Johnson syndrome (CR), 1272  
onychomycosis therapy, 1109  
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155  
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538  
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- study of effects of increasing doses of drug for nail fungus (CTR), 187, 425  
TDT 067 onychomycosis study (CTR), 1538
- Antihistamines**  
safety and efficacy of abatacept for chronic urticaria after inadequate response to (CTR), 86, 1155  
second-generation, for chronic idiopathic urticaria, 503  
topical, efficacy for pruritus, 992
- Antihypertensive drugs**, oral lichenoid drug reaction associated with hypoglycemic drugs and (CR), 73
- Antimicrobial drugs**  
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727  
antibacterial effects of a chitosan-containing spray, 1237  
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131  
avoiding antimicrobial resistance in treatment of acne vulgaris, 519  
benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80  
changes in rosacea comorbidities and treatment utilization over time, 1402  
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425  
development of antimicrobial resistance due to antibiotic treatment of acne, 655  
efficacy and safety of doxycycline and minocycline for acne, 1407  
efficacy of metronidazole in treatment of cutaneous and mucosal lichen planus, 1186  
efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607  
FDA Advisory Committee recommends approval of cefaroline fosamil (PP), 1552  
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241  
Tamiflu®: what dermatologists need to know (NVR), 76  
oregano-based ointment with antimicrobial activity against MRSA, 377  
retapamulin in age of *S. aureus* resistance to, 1198  
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538  
safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538  
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538  
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82  
sales of Zeftera stopped in Canada (PP), 874  
tigecycline linked to increased mortality risk (PP), 1455  
TR-701 for bacterial skin infections (CTR), 1538  
using off-patent antibiotics for MRSA (CTR), 1538
- Antioxidants**  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
dose-dependent antioxidant function of resveratrol, 1523  
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480  
N-acetylcysteine to reduce melanoma risk (PP), 183  
oxidative damage, skin aging, antioxidants and a

- novel antioxidant rating system, 11
- Anti-tumor necrosis factor-(TNF) therapy**  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab, 57
- cutaneous lupus erythematosus and (CR), 1283
- drug-associated acne and acneiform eruptions, 627
- efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82
- etanercept for chronic urticaria (CTR), 1155
- etanercept for familial pityriasis rubra pilaris (CR), 844
- etanercept for recalcitrant cicatricial pemphigoid (CR), 68
- etanercept in lichen planus (CTR), 187, 425, 577
- how and when to use biologics in psoriasis and, s106 (August)
- injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
- long-term safety and efficacy of etanercept in psoriasis, 928
- prospective new biologic therapies for psoriasis and psoriatic arthritis, 947
- rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
- safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577
- safety and effectiveness of etanercept for lichen planus or oral mucosa or skin (CTR), 883
- safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
- safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
- use in pediatric psoriasis, 975
- ustekinumab vs. etanercept for psoriasis (PP), 572
- Antiviral drugs**  
EPB-348 for herpes zoster (CTR), 1035
- FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
- Mylan receives approval for generic Valtrex® (PP), 1033
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Anxiety**, relaxation strategies for patients during dermatologic surgery, 795
- Apremilast**  
in atopic or contact dermatitis (CTR), 187
- for lichen planus (CTR), 577, 883
- for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446
- positive phase 2b clinical trial for psoriasis treatment (PP), 282
- for rosacea (CTR), 727, 1035, 1538
- safety study of clinical and immune effects in cutaneous lupus (CTR), 1538
- Arginine butyrate**, plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289
- Argyria**, localized, secondary to acupuncture (CR), 1019
- Aripiprazole**, drug-associated acne and acneiform eruptions, 627
- Artefill®**, for correction of atrophic acne scars, 1062
- Arthritis**  
pancreatitis, panniculitis and polyarthritis syndrome (CR), 1145
- psoriatic  
adult onset, certolizumab pegol for (CTR), 1446
- atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
- prospective new biologic therapies for psoriasis and, 947
- safety and efficacy of ustekinumab in patients who have prior exposure to anti-TNF agents (CTR), 1155
- Ascherson's syndrome**, drug therapy for, 341
- Asclera**. See Polidocanol
- ASP015K**, efficacy and safety in psoriasis (CTR), 1035, 1446
- Atacicept**, in generalized systemic lupus erythematosus (CTR), 1538
- Atopic dermatitis**  
adherence and efficacy of desonide hydrogel for, 324
- anakinra for (CTR), 1035, 1155, 1446
- apremilast in contact dermatitis or (CTR), 187
- cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for, 372
- effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883
- efficacy of triamcinolone 0.1% cream occluded with hydrogel patch vs. triamcinolone 0.1% cream without occlusion for (CTR), 883
- evidence-based review of coal tar preparations for, 1258
- management of pruritus with Xyzal in (CTR), 82
- mycophenolate mofetil for chronic dermatitis, 356
- nonsteroidal lamellar matrix cream containing palmytoyethanolamide for, 334
- pediatric indication for Locoid Lipocream® cream (PP), 80
- pediatric longitudinal evaluation of long-term safety of Protopic® for (CTR), 1446
- in pregnancy (NVR), 1297
- pruritus in, 488
- safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- topical vitamin B12 for children with (CTR), 1155, 1446
- treatment with concurrent Altanax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035
- Azathioprine**, drug-associated acne and acneiform eruptions, 627
- Azelaic acid**  
efficacy in psoriasis, 964
- efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
- vs. hydroquinone in melasma (CTR), 727
- B**  
**Basal cell carcinoma (BCC)**  
BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035
- celecoxib inhibition of genetic BCC (PP), 418
- efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 85, 289
- efficacy of itraconazole in (CTR), 883, 1035
- efficacy of PDT for recurrent SCC and BCC, 122
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1035
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- fractional photothermolysis for depressed alar scar following Mohs micrographic surgery for (CR), 66
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
- of nasal pyramid, intralesional interferon alfa-2b for, 381
- patient with nevroid BCC syndrome treated successfully with PDT (CR), 167
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
- rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
- Behçet's disease**  
multiple skin cancers in a patient on combination immunosuppressive therapy for (CR), 152
- thalidomide and analogues for, 814
- Benzoyl peroxide (BPO)**  
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131
- benzoyl peroxide-clindamycin combinations and skin hydration (PP), 80
- comparative study of tolerability of two combination therapies for acne (CTR), 187, 425
- dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33
- efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395
- efficacy of benzoyl peroxide emollient foam and benzoyl peroxide wash for acne on back, 622
- Epiduo® pediatric acne study (CTR), 1155
- irritation potential of tretinoin gel microsphere pump vs. adapalene plus benzoyl peroxide gel, 998
- morning/morning and morning/evening regimens of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805
- optimizing acne therapy with unique vehicles, s53 (May)
- properties of, 482
- Benzyl alcohol lotion 5%**, for head lice (PP), 572
- Beta-blockers**  
for chronic wound healing (CTR), 727
- drug-associated acne and acneiform eruptions, 627
- Betamethasone dipropionate**, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
- Bevacizumab**  
for angiosarcoma (CTR), 285
- gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- Bexarotene**  
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
- systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
- BFH722**, safety and efficacy in psoriasis patients (CTR), 187, 425
- Bicillin L-A**, vs. placebo for psoriasis unresponsive to topical medications (CTR), 425
- Bimatoprost**  
ophthalmic solution, in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446

**Biologics**

Briakinumab and, S106 (August)  
 How and when to use in psoriasis, S106 (August)  
 Prospective new biologic therapies for psoriasis and psoriatic arthritis and, 947  
 Use of biologic agents in pediatric psoriasis and, 975

**Biomaterials**

attaining predictable aesthetic results with dermal fillers, 458  
 Belotero dermal filler close to FDA approval (PP), 1455  
 calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446  
 collagen-glycosaminoglycan copolymer for severe chest keloids, 542  
 correction of atrophic acne scars with Artefill®, 1062  
 current and future botulinum neurotoxin type A preparations in aesthetics, 1065  
 effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097  
 efficacy of spray silicone in alteration of burn scar (CTR), 727  
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856  
 face and neck revitalization with platelet-rich plasma, 466  
 failure of botulinum toxin treatment for localized vitiligo, 1092  
 FDA approves Juvéderm® XC with lidocaine (PP), 418  
 fillers for facial shaping, s129 (August)  
 formulation composition of botulinum toxins in clinical use, 1085  
 histopathologic identification of dermal filler agents, 1072  
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135  
 injection techniques for revolumization of perioral region with hyaluronic acid, 367  
 localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399  
 Mederma® for stretch marks (PP), 418  
 minimally invasive techniques for periorbital rejuvenation, s118 (August)  
 monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690  
 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577  
 Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187  
 retrospective review of 500 patients treated with abobotulinumtoxinA, 1081  
 SkinMedical launches new Rejuvenize Peel™ (PP), 418  
 treatment of facial atrophic scars with Esthélics, 1507  
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538  
 use of injectable poly-L-lactic acid in people of color, 451  
 utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149

**Bisocetrol**, sunscreen update: controversies, what's safe, what's next (NVR), 1451  
**Blepharospasm**, acetyl hexapeptide-8 (AH8) in treatment of (CTR), 82  
**Blue light therapy**, current guide to laser and light-based therapies for acne, 614  
**BMS-833923 (XL139)**, in advanced or metastatic cancer (CTR), 883, 1035  
**Body contouring**  
 PureGraft™ System receives marketing clearance (PP), 723  
 Zeltiq receives FDA clearance (PP), 1552  
**Body image disturbance**, in patients with acne (RR), 725  
**Bone**, osteoinvasive subungual melanoma (CR), 159  
**Botanical products**  
 for actinic keratoses, s45 (May)  
 for alopecia, 537  
 cosmeceuticals in clinical practice, s62 (May)  
**Botulinum toxin**  
 cost effectiveness for treatment of depression, 27  
 current and future botulinum neurotoxin type A preparations in aesthetics, 1065  
 expanding the use of neurotoxins in facial aesthetics, s7 (January)  
 failure of treatment for localized vitiligo, 1092  
 FDA approves Merz Pharmaceuticals' Xeomin® (PP), 1455  
 formulation composition of botulinum toxins in clinical use, 1085  
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135  
 minimally invasive techniques for periorbital rejuvenation, s118 (August)  
 practical applications of a new type of, s31 (March)  
 for psoriasis (CTR), 82, 1035  
 to reduce itch (PP), 282  
 retrospective review of 500 patients treated with abobotulinumtoxinA, 1081  
 treatment of alopecia areata of scalp with intradermal injections of (CTR), 82  
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538  
**Brachytherapy**, electronic, for non-melanoma skin cancer (CTR), 1035  
**Breast surgery**, safety and efficacy of EXC 001 to improve appearance of scars from (CTR), 728  
**Briakinumab**  
 See also Biologics  
 for psoriasis and psoriatic arthritis, 947  
 use in pediatric psoriasis, 975  
**Brown recluse spider bite**, drug therapy for, 341  
**Bulimia nervosa**, dermatologic indicators of (NVR), 412  
**Bullous skin disorders**  
 autoimmune, hematopoietic stem cell support in patients with (CTR), 1289  
 efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289  
**Bupropion**, Stevens-Johnson syndrome with acute psoriatic exacerbation induced by (CR), 1010  
**Burn scars**  
 ablative fractional treatment of mature scars (CR), 389  
 appearance after CO2 fractional laser treatment (CTR), 727  
 CO2 fractional laser treatment of (CR), 173  
 efficacy of spray silicone in alteration of (CTR),

727

**Buruli ulcer**, drug therapy for, 341

**C****Calciphylaxis**

drug therapy for, 341  
 warfarin-induced skin necrosis mimicking (CR), 859

**Calcipotriene**

FDA approves Glenmark's calcipotriene ointment (PP), 723  
 safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969  
**Calcium dobesilate**, combination therapy for rosacea (CTR), 187, 285, 425, 1538  
**Calcium hydroxyapatite**  
 fillers for facial shaping, s129 (August)  
 histopathologic identification of dermal filler agents, 1072  
 in nonsurgical aesthetic rejuvenation, 446  
 pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577

**Capecitabine**, increased mast cell density in hand-foot syndrome induced by (CR), 268

**Capsaicin**

for alopecia, 537  
 FDA approves Qutenza® for postherpetic neuralgia (PP), 282  
**Cardiac catheterization dye**, fatal toxic epidermal necrolysis due to (CR), 837  
**Carotenoid levels in skin**, correlation with previous history of skin cancer (CTR), 1289  
**Cathelicidin**, effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883  
**CC-10004**. See Apremilast  
**CD07223 gel**, efficacy and safety study in subjects with acne (CTR), 1446  
**CD07805/47 gel**, efficacy and safety in subjects with facial erythema associated with rosacea (CTR), 1538

**CDP 870**. See Certolizumab pegol

**Ceftaroline fosamil**, FDA Advisory Committee recommends approval of (PP), 1552  
**Ceftobiprole**, sales stopped in Canada (PP), 874  
**Celecoxib**, inhibition of genetic BCC by (PP), 418  
**CEM-102**, safety and efficacy vs. linezolid in bacterial skin infections (CTR), 1538  
**Cephalexin**, using off-patent antibiotics for MRSA (CTR), 1538

**Certolizumab pegol (CDP 870)**

for adult onset psoriatic arthritis (CTR), 1446  
 for psoriasis and psoriatic arthritis, 947  
**Cetirizine**, for chronic idiopathic urticaria, 503  
**Cetuximab**, cutaneous reactions to epidermal growth factor receptor inhibitors, 1229  
**Charcot-Marie-Tooth disease**, multiple malignant melanomas and (CR), 164

**Chemotherapy**

bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577  
 botanicals for alopecia due to, 537  
 eruption secondary to Taxotere (CR), 1534  
 gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285  
 increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268  
 for infantile hemangiomas (NVR), 176  
 management of Merkel cell carcinoma with emphasis on small primary tumors, 105  
 sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma

- (CR), 169  
treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017  
urticarial hypersensitivity reaction caused by temozolomide (CR), 1142  
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Chilblains**, successful treatment with hydroxychloroquine, 1242
- Chitosan**, antibacterial effects of spray containing, 1237
- Chlorpromazine**, drug-associated acne and acneiform eruptions, 627
- Chronic granulomatous disease, X-linked**, voriconazole-induced photosensitivity/photodermatitis in (CR), 562
- Chronic lymphocytic leukemia**, dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- Cicatrical pemphigoid**  
etanercept for (CR), 68  
rituximab in (CTR), 187, 425, 577, 1289
- Ciclopirox**, antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
- Clarisonic Opal™**, novel sonic infusion system for periorbital rhytides, 1121
- Clindamycin**  
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel vs. clindamycin phosphate/tretinoin gel for acne vulgaris, 131  
benzoyl peroxide–clindamycin combinations and skin hydration (PP), 80  
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425  
properties of benzoyl peroxide combined with, 482  
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538  
using off-patent antibiotics for MRSA (CTR), 1538
- Clinical trial review** (CTR), 82, 187, 285, 425, 577, 727, 883, 1035, 1155, 1289, 1446, 1538
- Clinical trials**  
acetyl hexapeptide-8 (AH8) in treatment of blepharospasm (CTR), 82  
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727  
AIN457 regimen finding study in psoriasis (CTR), 285  
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82  
alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883  
anakinra for atopic dermatitis (CTR), 1035, 1155, 1446  
antibacterial effects of a chitosan-containing spray, 1237  
anti-inflammatory effects of topical dapsone for acne, 667  
apremilast for lichen planus (CTR), 577, 883  
apremilast for moderate-to-severe acne (CTR), 727, 1155, 1289, 1446  
apremilast for rosacea (CTR), 727, 1035, 1538  
apremilast in atopic or contact dermatitis (CTR), 187  
arginine butyrate plus standard local therapy in patients with refractory sickle cell ulcers (CTR), 1289  
assessment of mechanisms of improved wound healing (CTR), 727  
atacept in generalized systemic lupus erythematosus (CTR), 1538  
Atralin gel for rosacea (CTR), 1035, 1538  
azelaic acid vs. hydroquinone in melasma (CTR), 727  
benzoyl peroxide–clindamycin combinations and skin hydration (PP), 80  
beta-blocker for chronic wound healing (CTR), 727  
bevacizumab for angiosarcoma (CTR), 287  
bicillin LA vs. placebo for psoriasis unresponsive to topical medications (CTR), 425  
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577  
BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035  
botulinum toxin to treat psoriasis (CTR), 82, 1035  
burn scar appearance after CO2 fractional laser treatment (CTR), 727  
certolizumab pegol for adult onset psoriatic arthritis (CTR), 1446  
clinical activity, safety, and tolerability of SRT2104 in subjects with psoriasis (CTR), 1446  
Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial (PP), 723  
combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289  
combination therapy for rosacea (CTR), 187, 285, 425, 1538  
comparative study of tolerability of two combination therapies for acne (CTR), 187, 425  
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289  
comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229  
comparison of SUBA™-itraconazole with SPO-RANOX® onychomycosis (CTR), 187, 285, 425  
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
correlation between skin carotenoid levels and previous history of skin cancer (CTR), 1289  
dapsone gel 5% for dermatitis herpetiformis (CTR), 1155  
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33  
dasatinib for unresectable or metastatic SCC (CTR), 285  
dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883  
dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883  
dose finding study of AEB071 assessing psoriasis area and severity index in patients with plaque psoriasis (CTR), 285  
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097  
effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883  
effect of thymosin beta-4 on wound healing in epidermolysis bullosa (CTR), 727  
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155  
effects of pulsed-dye laser on scar formation (CTR), 727, 1155  
effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289  
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82  
efficacy and safety of ASP015K in psoriasis (CTR), 1035, 1446  
efficacy and safety of CD07223 gel in subjects with acne (CTR), 1446  
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with rosacea (CTR), 1538  
efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285  
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155  
efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289  
efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446  
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101  
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480  
efficacy of 15% azelaic acid in psoriasis, 964  
efficacy of hexapeptide-7 on menopausal skin, 49  
efficacy of itraconazole in BCC (CTR), 883, 1035  
efficacy of spray silicone in alteration of burn scar (CTR), 727  
efficacy of triamcinolone 0.1% cream occluded with hydrogel patch vs. triamcinolone 0.1% cream without occlusion for eczema (CTR), 883  
efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035  
electronic brachytherapy for non-melanoma skin cancer (CTR), 1035  
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
EPB-348 for herpes zoster (CTR), 1035  
Epiduo® pediatric acne study (CTR), 1155  
erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285  
erlotinib for psoriasis (CTR), 82, 187, 285, 425, 577, 1035, 1446  
erlotinib in women with SCC of vulva (CTR), 1289  
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289  
Ertaczo® relieves itching (PP), 80  
etanercept for chronic urticaria (CTR), 1155  
etanercept in lichen planus (CTR), 187, 425, 577  
evaluation of single dose of ILV-095 in psoriasis subjects (CTR), 285, 577, 1035, 1446  
exSALT SD7™ compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727  
face and neck revitalization with platelet-rich plasma, 466  
fluphenazine hydrochloride for psoriasis (CTR), 187, 425, 1446  
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035  
gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 290  
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289  
Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446

- Helix BioPharma and topical interferon alpha-2b for anogenital warts (PP), 723
- hematopoietic stem cell support in patients with autoimmune bullous skin disorders (CTR), 1289
- human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883
- hydroxychloroquine efficacy in chronic urticaria (CTR), 1155
- imatinib in scleroderma (PP), 80
- injectable biologic and U0279 combination therapy for psoriasis (CTR), 285
- ipilimumab in young patients with advanced or refractory solid tumors (CTR), 883
- IVIG with or without cyclophosphamide in pemphigus (CTR), 1289
- laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155
- lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883
- light therapy for toenail fungus (CTR), 285, 577, 1155
- long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647
- long-term safety and efficacy of etanercept in psoriasis, 928
- MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- management of pruritus with Xyzal in atopic dermatitis (CTR), 82
- minoxidil for female pattern hair loss (CTR), 1446
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035
- MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577
- Nd:YAG laser for acne keloidalis nuchae (CTR), 577
- nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
- novel treatment for syndromic ichthyoses (CTR), 1155
- oral glutamine to suppress recurrent herpes labialis (CTR), 285
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- PDT using ALA in treating patients with skin cancer (CTR), 82
- PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425
- pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446
- PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
- pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
- phase 1 study of ND0611 dermal patch (PP), 1033
- pimecrolimus cream for cutaneous lesions of pemphigus vulgaris, 684
- positive phase 2b clinical trial of psoriasis drug apremilast (PP), 282
- randomized clinical studies of adapalene lotion for acne, 639
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- retapamulin vs. linezolid in treatment of SITL or impetigo due to MRSA (CTR), 82, 1538
- rituximab in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289
- safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883
- safety and efficacy of abatacept in subjects with chronic urticaria after inadequate response to antihistamine therapy (CTR), 82, 1155
- safety and efficacy of BFH772 in psoriasis patients (CTR), 189, 425
- safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538
- safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1035, 1538
- safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538
- safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 728
- safety and efficacy of IDP-107 in patients with acne vulgaris (CTR), 1446
- safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538
- safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82
- safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549
- safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446
- safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035
- safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289
- safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
- safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
- safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1035, 1155, 1446
- Soligenix study of orBec® for prevention of GVHD (PP), 1033
- spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
- study of effects of increasing doses of drug for nail fungus (CTR), 189, 427
- TDT 067 onychomycosis study (CTR), 1538
- terminology for vehicle vs. placebo in, 1221
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- tolerability and efficacy of two topical therapies for keloids and hypertrophic scars, 514
- topical cidofovir for prevention of hair growth (CTR), 82
- topical cyclosporin for ocular rosacea (CTR), 285
- topical perillyl alcohol in treating patients with sun damaged skin and AK (CTR), 82
- topical vitamin B12 for childhood atopic dermatitis (CTR), 1155, 1446
- topically dissolved oxygen (TDO) to ameliorate signs of photodamage (CTR), 187, 425
- TR-701 for bacterial skin infections (CTR), 1538
- treating onychomycosis (CTR), 187, 425, 1538
- treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220
- treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- treatment of atopic dermatitis with concurrent Altabax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
- treatment of surgical scars with pulsed dye laser (CTR), 727
- trial of Dermacorder for detecting malignant skin lesions (CTR), 883
- Trius Therapeutics phase 3 study of torezolid phosphate (PP), 1160
- using off-patent antibiotics for MRSA (CTR), 1538
- UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
- vaccine therapy in stage IV cutaneous melanoma (CTR), 1292
- VB-201 for psoriasis (CTR), 1037, 1449
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 885
- Clobetasol propionate**, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- CNTO-148**. See Golimumab
- CNTO-1275**. See Ustekinumab
- Coal tar preparations**, evidence-based review in treatment of psoriasis and atopic dermatitis, 1258
- Coffea arabica extract**
- efficacy and tolerance of novel phenolic antioxidant skin care system containing, 1480
- oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
- Colchicine**, in treatment of morphea, 1213
- Collagen**
- fillers for facial shaping, s129 (August)
- histopathologic identification of dermal filler agents, 1072
- Collagen-glycosaminoglycan copolymer**, for severe chest keloids, 542
- Colloidal oatmeal**, 1116
- Combat dermatology**, prevalence of skin disease in deployed dermatology clinic in Iraq, 210
- Complement**
- potential role in immune evasion by *Mycobacterium leprae*, 1373
- role in dendritic cell control of T-cell subsets (editorial), 1364
- Contact dermatitis**
- apremilast in atopic dermatitis or (CTR), 187
- thalidomide and analogues for, 814
- CoolSculpting**, Zeltiq receives FDA clearance (PP), 1552
- Copper zinc malonate complex**, plus hydroquinone and tretinoin for treating photodamage of décolletage area, 220
- Corticosteroids**
- adherence and efficacy of desonide hydrogel for atopic dermatitis, 324
- drug-associated acne and acneiform eruptions, 627
- FDA approval of mometasone furoate topical solution USP, 0.1% (PP), 1455

- hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514  
for infantile hemangiomas (NVR), 176  
for infantile hemangiomas, immune function impaired by (PP), 1033  
pediatric indication for Locoid Lipocream® cream (PP), 80  
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969  
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41  
treatment of atopic dermatitis with concurrent Altabax® and topical low-potency corticosteroids vs. low-potency corticosteroid monotherapy (CTR), 883, 1035  
versus. tacrolimus for pruritus in atopic dermatitis, 488  
in treatment of morphea, 1213
- Cosmetic dermatology**  
attaining predictable aesthetic results with dermal fillers, 458  
Belotero dermal filler close to FDA approval (PP), 1455  
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
correction of atrophic acne scars with Artefill®, 1062  
cosmeceuticals in clinical practice, s62 (May)  
current and future botulinum neurotoxin type A preparations in aesthetics, 1065  
dermal effects of nanoparticles, 475  
effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097  
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480  
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
expanding the use of neurotoxins in facial aesthetics, s7 (January)  
face and neck revitalization with platelet-rich plasma, 466  
failure of botulinum toxin treatment for localized vitiligo, 1092  
FDA approves Juvéderm® XC with lidocaine (PP), 418  
first fractional laser FDA cleared for stretch marks (PP), 418  
formulation composition of botulinum toxins in clinical use, 1085  
histopathologic identification of dermal filler agents, 1072  
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy (BC), 1135  
injection techniques for revolumization of perioral region with hyaluronic acid, 367  
lip tenting technique, 559  
localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399  
Mederma® for stretch marks (PP), 418  
minimally invasive techniques for periorbital rejuvenation, s118 (August)  
novel sonic infusion system for periorbital rhytides, 1121  
pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577  
practical applications of a new botulinum toxin, s31 (March)  
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16  
PureGraft™ System receives marketing clearance (PP), 723  
retrospective review of 500 patients treated with abobotulinumtoxinA, 1081  
SkinMedica launches new Rejuvenize Peel™ (PP), 418  
SmartLipoTriplex™ for liposuction (PP), 80  
Solta Medical to buy Aesthera Corp. (PP), 418  
treatment of facial atrophic scars with Esthélics, 1507  
use of injectable poly-L-lactic acid in people of color, 451  
Zerona now FDA-approved for body slimming (PP), 1455
- Cost effectiveness**, of botulinum toxins for treatment of depression, 27
- Coumadin necrosis**, drug therapy for, 341
- Cow udder ointment**, drug-associated acne and acneiform eruptions, 627
- Cryopneumatic technology**, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528
- Cryosurgery**  
for actinic keratoses, s45 (May)  
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101  
medical and surgical management of keloids, 1249  
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- CTLA4 therapy**, autoimmune complications of (CR), 1432
- Cutaneous aging**. See also Photoaging  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
efficacy of hexapeptide-7 on menopausal skin, 49  
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
- Cutaneous angioimmunoblastic T-cell lymphoma** (CR), 851
- Cutaneous lupus erythematosus**  
anti-TNF- $\alpha$  therapy and (CR), 1283  
development associated with use of imiquimod to treat AK (CR), 1022  
in pregnancy (NVR), 1297  
thalidomide and analogues for, 814
- Cutaneous necrosis, acute**, drug therapy for, 341
- Cutaneous pseudolymphoma**, ALA-PDT for (CR), 688
- Cutaneous T-cell lymphoma**  
alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883  
angioimmunoblastic (CR), 851  
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014  
human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883  
Istodax for (PP), 183  
lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883  
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888  
role of phototherapy in, 764  
maintenance phototherapy, 800
- successful treatment with topical 5-fluorouracil (CR), 1017  
thalidomide and analogues for, 814
- Cyclophosphamide**, IVIG with or without, in pemphigus (CTR), 1289
- Cyclosporine**  
drug-associated acne and acneiform eruptions, 627  
non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277  
ophthalmic solution, for ocular rosacea (CTR), 285
- Cytokines**, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330

## D

- Dabo**, for alopecia, 537
- Dactinomycin**, drug-associated acne and acneiform eruptions, 627
- Danazol**, drug-associated acne and acneiform eruptions, 627
- Dantrolene**, drug-associated acne and acneiform eruptions, 627
- Dapsone**  
anti-inflammatory effects of topical dapsone for acne, 667  
dapsone gel 5% for dermatitis herpetiformis (CTR), 1155  
dapsone gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33  
drug-associated acne and acneiform eruptions, 627  
safety in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532
- Dasatinib**  
for unresectable or metastatic SCC (CTR), 285  
for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- Decubitus ulcers**, oxandrolone treatment of (CR), 711
- Delusions of parasitosis**, aripiprazole for (CR), 1531
- Dendritic cells in immunotherapy**  
potential role for complement in immune evasion by Mycobacterium leprae, 1373  
role of complement in dendritic cell control of T-cell subsets (editorial), 1364  
T cells and, 1383  
TH17 in regression of metastatic melanoma to topical diphenhydramine, 1368
- Depression**, cost effectiveness of botulinum toxins for treatment of, 27
- Dermacorder**, for detecting malignant skin lesions (CTR), 883
- Dermatitis herpetiformis**, dapsone gel 5% for (CTR), 1155
- Dermatologists**  
approaching psoriasis: patient-physician relationships, patient education and choosing the right topical vehicle, 908  
identifying the right dermatologic surgery fellowship for you (RR), 421
- Dermatomyositis**, Wong type, 1475
- Dermoscopy**, impact on skin cancer diagnostics, 129
- Desloratadine**, for chronic idiopathic urticaria, 503
- Desonide hydrogel**, adherence and efficacy for atopic dermatitis, 324
- Devices and equipment**  
AccuView DV-5 Multi Imaging System (PP), 418  
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82,

187, 425, 1035, 1155, 1289  
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK (PP), 1552  
 FDA approval of eMatrix device (PP), 572  
 FDA approves Exilis body shaping as nonsurgical device (PP), 874  
 FDA approves Ulthera's ultrasound product (PP), 282  
 FDA panel makes tanning bed recommendations (PP), 874  
 flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268  
 Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183  
 Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446  
 modified scalpel in hair restoration, 1266  
 MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577  
 novel sonic infusion system for periorbital rhytides, 1121  
 PureGraft™ System receives marketing clearance (PP), 723  
 single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341  
 tattoo treatment with alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam, 1333  
 TempASSURE device (PP), 418  
 trial of Dermacorder for detecting malignant skin lesions (CTR), 883  
 VECTRA M3 facial imaging system (PP), 418  
 Zeltiq receives FDA clearance (PP), 1552  
 Zerona now FDA-approved for body slimming (PP), 1455

**Diabetes mellitus**  
 iron overload and diabetic wounds (NVR), 719  
 prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455  
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82

**Diet/nutrition**, Heliocare® (PP), 183

**Diphencyprone, topical**, TH17 in regression of metastatic melanoma to, 1368

**DNA repair enzyme creams**, reduced number of AK with, 1519

**Docetaxel**  
 eruption secondary to (CR), 1534  
 and gemcitabine with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285

**Doxycycline**  
 efficacy and safety of doxycycline and minocycline for acne, 1407  
 efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607  
 safety of topical gel for adult diabetic lower extremity ulcers (CTR), 82

**Drug delivery**  
 hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135  
 safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500  
 stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by cryopneumatic and photopneumatic technologies, 1528

**Drug reactions/toxicity**  
 annular leukocytoclastic vasculitis associated with sorafenib (CR), 697  
 atypical presentation of histoplasmosis in a

patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
 bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation (CR), 1010  
 cutaneous fixed drug eruption to fluconazole (CR), 1025  
 cutaneous lupus erythematosus and anti-TNF- $\alpha$  therapy (CR), 1283  
 cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439  
 cutaneous reactions to epidermal growth factor receptor inhibitors, 1229  
 dermatologic emergencies (NVR), 1545  
 development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014  
 development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022  
 drug-associated acne and acneiform eruptions, 627  
 eruption secondary to Taxotere (CR), 1534  
 fatal toxic epidermal necrolysis due to cardiac catheterization dye (CR), 837  
 fluconazole-associated Stevens-Johnson syndrome (CR), 1272  
 increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268  
 isotretinoin and inflammatory bowel disease and (NVR), 278  
 levetiracetam-induced reticulated drug eruption (CR), 409  
 non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277  
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73  
 postpubertal eruptive syringoma triggered with antiepileptic drugs (CR), 707  
 progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005  
 red man syndrome (NVR) and, 76  
 sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma (CR), 169  
 Tamiflu®, and 76  
 tigecycline linked to increased mortality risk (PP), 1455  
 urticarial hypersensitivity reaction caused by temozolomide (CR), 1142  
 voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562  
 warfarin-induced skin necrosis mimicking calciphylaxis (CR), 859

**Drug resistance**  
 avoiding antimicrobial resistance in treatment of acne, 519  
 development of antimicrobial resistance due to antibiotic treatment of acne, 655  
 methicillin-resistant *S. aureus* infection, new antibiotics for, and (NVR), 76  
 oregano-based ointment with antimicrobial activity against, 377  
 retapamulin vs. linezolid in treatment of SITL and impetigo due to (CTR), 82, 1545  
 Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282  
 using off-patent antibiotics for (CTR), 1538  
 retapamulin in age of *S. aureus* antimicrobial resistance, 1198

**E**

**Eating disorders**, dermatologic indicators of (NVR), 412

**Ecallantide**, FDA approval for hereditary angioedema (PP), 572

**Economic issues**  
 cost effectiveness of botulinum toxins for treatment of depression, 27  
 cost-effectiveness of tacrolimus ointment vs. pimecrolimus cream for atopic dermatitis, 372  
 Solta Medical to buy Aesthera Corp. (PP), 418

**Ecthyma gangrenosum**, drug therapy for, 341

**Eczema**. See Atopic dermatitis

**Editorials**  
 Miami heat (editorial), 208  
 role of complement in dendritic cell control of T-cell subsets, 1364  
 we are making progress with acne and rosacea, 603

**Efalizumab**  
 how and when to use biologics in psoriasis, s106 (August)  
 progressive multifocal leukoencephalopathy in two psoriasis patients treated with (CR), 1005  
 for resistant plaque psoriasis (PP), 183  
 use in pediatric psoriasis, 975

**Emergencies, dermatologic (NVR)**, 1545

**EPB-348**, for herpes zoster (CTR), 1035

**Epidermal growth factor receptor inhibitors**  
 cutaneous reactions to, 1229  
 drug-associated acne and acneiform eruptions, 627

**Epidermolysis bullosa**, effect of thymosin beta-4 on wound healing in (CTR), 727

**Epigallocatechin gallate (EGCG)**  
 for cancer-related alopecia, 537  
 cosmeceuticals in clinical practice, s62 (May)

**Erbix®**. See Cetuximab

**Erlotinib**  
 cutaneous reactions to epidermal growth factor receptor inhibitors, 1229  
 drug-associated acne and acneiform eruptions, 627  
 prior to surgery or radiation in patients with SCC (CTR), 883, 1289  
 for psoriasis (CTR), 82, 187, 285, 425, 577, 1035, 1446  
 and radiotherapy for cutaneous SCC (CTR), 82, 285

**Ertaczo®**. See Sertaconazole nitrate cream

**Eruptive syringoma**, postpubertal, triggered with antiepileptic drugs (CR), 707

**Erythema nodosum leprosum**, thalidomide and analogues for, 814

**Erythromelalgia**, gabapentin for (CR), 565

**Estrogen**, efficacy of hexapeptide-7 on menopausal skin, 49

**Etanercept**  
 for chronic urticaria (CTR), 1155  
 efficacy and safety of adding methotrexate to, in psoriasis (CTR), 82  
 for familial pityriasis rubra pilaris (CR), 844  
 how and when to use biologics in psoriasis, s106 (August)  
 in lichen planus (CTR), 187, 425, 577  
 long-term safety and efficacy in psoriasis, 928  
 for recalcitrant cicatricial pemphigoid (CR), 68  
 safety and effectiveness for lichen planus of oral mucosa or skin (CTR), 577, 883  
 safety and efficacy in discoid lupus erythematosus (CTR), 1538  
 and U0279 combination therapy for psoriasis (CTR), 285  
 use in pediatric psoriasis, 975

- versus ustekinumab for psoriasis (PP), 572
- Etretinate**, drug-associated acne and acneiform eruptions, 627
- EXC 001**, safety and efficacy to improve appearance of scars from prior breast surgery (CTR), 728
- Exfoliative erythroderma** (NVR), 1545
- exSALT SD7™**, compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727
- Eye drops**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
- Eyebrow**  
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577  
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
- Eyelashes**, bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577
- Eyelid**, acetyl hexapeptide-8 (AH8) in treatment of blepharospasm (CTR), 82
- Ezetimibe**, hair growth in patients with alopecia areata totalis after treatment with simvastatin and (CR), 62
- F**
- Facial lipatrophy**, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690
- Facial rejuvenation**  
calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446  
Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
face and neck revitalization with platelet-rich plasma, 466  
fillers for facial shaping, s129 (August)  
hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135  
minimally invasive techniques for periorbital rejuvenation, s118 (August)  
MyoScience Tissue Remodeling Device for (CTR), 577  
SkinMedical launches new Rejuvenize Peel™ (PP), 418
- Famciclovir**, safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Familial pityriasis rubra pilaris** (CR), 844
- Fat**  
autologous, for facial shaping, s129 (August)  
dual-wavelength laser lipolysis treatment of lipomas (CR), 387  
fat necrosis/panniculitis and polyarthritis associated with pancreatic acinar cell carcinoma (CR), 1145  
fat transplant in treatment of morphea, 1213  
FDA issues warning letters about claims regarding lipodissolve (PP), 874  
laser lipolysis with 980 nm diode laser, s58 (May)  
monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690  
PureGraft™ System receives marketing clearance (PP), 723  
SmartLipo Triplex™ for liposuction (PP), 80
- Zeltiq receives FDA clearance (PP), 1552
- Fellowships**, identifying the right dermatologic surgery fellowship for you (RR), 421
- Fexofenadine**, for chronic idiopathic urticaria, 503
- Field cancerization**, for actinic keratoses, s45 (May)
- Fluconazole**  
cutaneous fixed drug eruption to (CR), 1025  
Stevens-Johnson syndrome associated with (CR), 1272
- Fluocinolone acetonide**, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- 5-Fluorouracil**  
medical and surgical management of keloids, 1249  
topical  
successful treatment of cutaneous T-cell lymphoma with topical (CR), 1017  
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Fluphenazine hydrochloride**, for psoriasis (CTR), 187, 425, 1446
- Foot lesions**  
efficacy and safety of new topical keratolytic treatment for palmoplantar keratoderma, 1512  
gabapentin for erythromelalgia (CR), 565  
increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268  
prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455  
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 82
- Fractional eyelift**, prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser, 16
- Fractionated laser therapy**  
appearance of burn scar after CO2 fractional laser treatment (CTR), 727  
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 84, 187, 425, 1035, 1155, 1289  
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155  
first fractional laser FDA cleared for stretch marks (PP), 418  
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66  
Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183  
of mature thermal burn scars (CR), 389  
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16  
treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420  
ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328
- Fungal infection**  
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525  
comparison of SUBA™-itraconazole with SPO-RANOX® for onychomycosis (CTR), 187, 285, 425  
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155  
light therapy for toenail fungus (CTR), 285, 577, 1155  
onychomycosis therapy, 1109
- pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155  
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538  
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538  
study of effects of increasing doses of drug for nail fungus (CTR), 187, 425  
TDT 067 onychomycosis study (CTR), 1538  
treating onychomycosis (CTR), 187, 425  
**FV-100**, vs. valacyclovir for herpes zoster (CTR), 1035
- G**
- Gabapentin**, for erythromelalgia (CR), 565
- Garlic**, for alopecia, 537
- GDC-0449**, efficacy and safety in patients with advanced BCC (CTR), 82, 285
- Gefitinib**  
cutaneous reactions to epidermal growth factor receptor inhibitors, 1229  
drug-associated acne and acneiform eruptions, 627  
for recurrent or metastatic SCC of skin (CTR), 883
- Gemcitabine**, and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- Genetics**  
celecoxib inhibition of genetic BCC (PP), 418  
pathogenesis, genetics and medical treatment of patterned hair loss, 1412  
steroid sulfatase gene deletion in Egyptian males with X-linked ichthyosis, 1192  
voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
- Genital warts**, FDA approves new indications for HPV vaccine (PP), 80
- Glaucoma drugs**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289
- Glucose-6-phosphate dehydrogenase deficiency**, safety of dapsone in, 532
- Glutamine**, to suppress recurrent herpes labialis (CTR), 285
- Glycolic acid**, tolerability and efficacy of novel formulation in treatment of melasma, 215
- Gold**, drug-associated acne and acneiform eruptions, 627
- Golimumab**, for psoriasis and psoriatic arthritis, 947
- Graft-versus-host disease (GVHD)**, Soligenix study of orBec® for prevention of (PP), 1033
- Granulocyte colony-stimulating factor**, drug-associated acne and acneiform eruptions, 627
- Green tea**  
for cancer-related alopecia, 537  
cosmeceuticals in clinical practice, s62 (May)
- GSK2132231A antigen-specific immunotherapeutic**, in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
- H**
- Hair**  
modified scalpel in hair restoration (BC), 1266  
topical cidofovir for prevention of hair growth (CTR), 82
- Hair loss**  
bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577  
botanical approaches to alopecia, 537

- hair growth in patients with alopecia areata totalis after treatment with simvastatin and ezetimibe (CR), 62
- Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446
- minoxidil for female pattern hair loss (CTR), 1446
- new study implicates autoimmune mechanisms in alopecia areata (PP), 1160
- pathogenesis, genetics and medical treatment of patterned hair loss, 1412
- safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446
- spironolactone pills vs. minoxidil lotion in female pattern hair loss (CTR), 577
- treatment of alopecia areata of scalp with intradermal injections of botulinum toxin (CTR), 82
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Hairmax Lasercomb** for androgenetic alopecia in females (CTR), 1446
- treatment of androgenetic alopecia in females, 12 beam (CTR), 1446
- Halobetasol propionate ointment**, efficacy of Ultravate ointment in combination with Lac-Hydrin cream for psoriasis (CTR), 285, 577, 1035
- Halogens**, drug-associated acne and acneiform eruptions, 627
- Hand lesions**
- efficacy and safety of new topical keratolytic treatment for palmoplantar keratoderma, 1512
- increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
- rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713
- unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841
- Hand sanitizers**, FDA warns consumers in Puerto Rico of harmful bacteria in (PP), 874
- Head lice**, benzyl alcohol lotion 5% for (PP), 572
- Hedgehog pathway inhibitor**, efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
- Heliocare**® (PP), 187
- Hemangiomas, infantile**
- corticosteroid treatment impairs immune function (PP), 1033
- current treatments for (NVR), 176
- pulsed dual-wavelength 595 and 1064 nm in management of, 310
- Hemodialysis patients**, safety and efficacy of oral nalfurafine HCl (AC-820) for uremic pruritus in (CTR), 82
- Hemostasis**, comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137
- Heparin necrosis**, drug therapy for, 341
- Herbal remedies**
- for alopecia, 537
- oregano-based ointment with antimicrobial activity against MRSA, 377
- Hereditary angioedema**, FDA approval of ecalantide for (PP), 572
- Hereditary hemochromatosis** (NVR), 719
- Herpes gestationis** (NVR), 1297
- Herpetic disease**
- EPB-348 for herpes zoster (CTR), 1035
- FDA approves Qutenza® for postherpetic neuralgia (PP), 282
- FV-100 vs. valacyclovir for herpes zoster (CTR), 1035
- oral glutamine to suppress recurrent herpes labialis (CTR), 285
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Hexapeptide-7**, efficacy on menopausal skin, 49
- Histology**
- annular leukocytoclastic vasculitis associated with sorafenib (CR), 697
- cutaneous fixed drug eruption to fluconazole (CR), 1025
- cutaneous lupus erythematosus and anti-TNF- $\alpha$  therapy (CR), 1283
- eruption secondary to Taxotere (CR), 1534
- familial pityriasis rubra pilaris (CR), 844
- histopathologic identification of dermal filler agents, 1072
- immunostains used in Mohs surgery, 760
- increased mast cell density in capecitabine-induced hand-foot syndrome (CR), 268
- intralesional interferon alfa-2b for BCC of nasal pyramid, 381
- isotretinoin-induced effects of mast cells on wound healing, 1207
- lichen planus pigmentosus (CR), 841
- localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
- localized argyria secondary to acupuncture (CR), 1019
- macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393
- Mohs surgery for melanoma in situ, 786
- nephrogenic systemic fibrosis, 829
- non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277
- oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73
- osteoinvasive subungual melanoma (CR), 159
- pancreatitis, panniculitis and polyarthritides syndrome (CR), 1145
- porokeratosis in patient with hepatitis of unclear etiology (CR), 258
- postpubertal eruptive syringoma triggered with antiepileptic drugs (CR), 707
- primary cutaneous angioimmunoblastic T-cell lymphoma (CR), 851
- rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702
- sorafenib-induced psoriasiform eruption in patient with metastatic thyroid carcinoma (CR), 169
- TH17 in regression of metastatic melanoma to topical diphenacyclone, 1368
- urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
- Wong type dermatomyositis, 1475
- Histoplasmosis**, atypical presentation in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57
- Hodgkin's lymphoma**, development under bexarotene treatment for Sézary syndrome (CR), 1014
- Human immunodeficiency virus (HIV) disease**, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in (CR), 690
- Human papillomavirus (HPV) vaccine**, FDA approves new indications for (PP), 80
- Hyaluronic acid (HA)**
- Belotero dermal filler close to FDA approval (PP), 1455
- effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097
- fillers for facial shaping, s129 (August)
- histopathologic identification of dermal filler agents, 1072
- hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
- injection techniques for revolumization of perioral region with, 367
- localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399
- monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- treatment of facial atrophic scars with Esthélics, 1507
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid vs. botulinum toxin injection alone (CTR), 1538
- Hydantoin**, drug-associated acne and acneiform eruptions, 627
- Hydrocortisone**
- hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514
- pediatric indication for Locoid Lipocream® cream (PP), 80
- Hydrophilic molecules**, stratum corneum permeation and percutaneous drug delivery enhanced by cryopneumatic and photopneumatic technologies, 1528
- Hydroquinone**
- vs. azelaic acid in melasma (CTR), 727
- tolerability and efficacy of novel formulation in treatment of melasma, 215
- treating photodamage of décolletage area with novel copper zinc malonate complex plus tretinoin and, 220
- Hydroxychloroquine**
- efficacy in chronic urticaria (CTR), 1155
- successful treatment of perniosis with, 1242
- Hydroxyzine**, Mylan receives approval for hydroxyzine hydrochloride tablets (PP), 1160
- Hyperhidrosis**, practical applications of a new botulinum toxin, s31 (March)
- Hyperkeratosis**, efficacy and safety of new topical keratolytic treatment for, 1512
- Hypersensitivity reactions**. See also Drug reactions/toxicity
- fatal toxic epidermal necrolysis due to cardiac catheterization dye (CR), 837
- sublingual immunotherapy against latex sensitivity (PP), 183
- urticarial hypersensitivity reaction caused by temozolomide (CR), 1142
- Hypoglycemic drugs**, oral lichenoid drug reaction associated with antihypertensive drugs and (CR), 73
- Hypothalamic-pituitary-adrenal (HPA) axis**, safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969
- Ichthyoses**, syndromic, novel treatment for (CTR), 1155
- Ichthyosis**, X-linked, steroid sulfatase gene deletion in Egyptian males with, 1192
- Idiopathic guttate hypomelanosis**, pimecrolimus for (BC), 238

- IDP-107**, safety and efficacy in patients with acne vulgaris (CTR), 1446
- IDP-108**, topical, safety and efficacy vs. vehicle in onychomycosis (CTR), 285, 577, 1538
- ILV-095**, evaluation of single dose in psoriasis subjects (CTR), 285, 577, 1035, 1446
- Imatinib**  
drug-associated acne and acneiform eruptions, 627  
in scleroderma (PP), 80
- Imiquimod cream**  
for actinic keratoses, s45 (May)  
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022  
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101  
FDA approves Zyclara™ (PP), 723  
generic approval of (PP), 572  
for infantile hemangiomas (NVR), 176  
medical and surgical management of keloids, 1249  
Perrigo announces FDA approval for (PP), 1552  
in treatment of morphea, 1213
- Immune function**  
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432  
effect of pimecrolimus cream on cathelicidin levels in eczema (CTR), 883  
impaired by corticosteroids for infantile hemangiomas (PP), 1033  
isotretinoin-induced effects of mast cells on wound healing, 1207  
statins in skin, 921  
ustekinumab effects on primate/human antigen-recall and humoral immune response functions, 677
- Immunomodulators**  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
development of subacute cutaneous lupus erythematosus associated with use of imiquimod to treat AK (CR), 1022  
drug-associated acne and acneiform eruptions, 627  
etanercept for chronic urticaria (CTR), 1155  
etanercept for familial pityriasis rubra pilaris (CR), 844  
etanercept for recalcitrant cicatricial pemphigoid (CR), 68  
etanercept in lichen planus (CTR), 187, 425, 577  
generic approval of imiquimod cream 5% (PP), 572  
how and when to use biologics in psoriasis, s106 (August)  
injectable biologic and U0279 combination therapy for psoriasis (CTR), 285  
long-term safety and efficacy of etanercept in psoriasis, 928  
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005  
prospective new biologic therapies for psoriasis and psoriatic arthritis, 947  
rapid improvement of pyoderma gangrenosum after infliximab treatment (CR), 702  
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577  
safety and effectiveness of etanercept for lichen planus or oral mucosa or skin (CTR), 883  
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538  
safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155  
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in cutaneous lupus (CTR), 1538  
thalidomide and analogues, 814  
use in biologic therapies in pediatric psoriasis, 975  
ustekinumab vs. etanercept for psoriasis (PP), 572
- Immunosuppression**, multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152
- Immunotherapy**  
dendritic cells and T cells in, 1383  
dendritic cells in  
potential role for complement in immune evasion by *Mycobacterium leprae*, 1373  
role of complement in dendritic cell control of T-cell subsets (editorial), 1364  
TH17 in regression of metastatic melanoma to topical diphenylprone, 1368  
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289  
IV immunoglobulin therapy for scleromyxedema (CR), 263  
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289  
sublingual, against latex sensitivity (PP), 183
- Impetigo**  
impetigo herpeticiformis in pregnancy (NVR), 1297  
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538
- Incobotulinumtoxin A**. See also Botulinum toxin  
FDA approves Merz Pharmaceuticals' Xeomin® (PP), 1455
- Incontinentia pigmenti**, delayed onychodystrophy of, 350
- Indoor tanning tax** (PP), 282
- Infantile hemangiomas**  
current treatments for (NVR), 176  
pulsed dual-wavelength 595 and 1064 nm in management of, 310
- Infection**  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
dermatologic emergencies (NVR), 1545  
EPB-348 for herpes zoster (CTR), 1035  
FDA Advisory Committee recommends approval of ceftaroline fosamil for (PP), 1552  
FV-100 vs. valacyclovir for herpes zoster (CTR), 1035  
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241  
new agents for MRSA (NVR), 76  
oral glutamine to suppress recurrent herpes labialis (CTR), 285  
oregano-based ointment with antimicrobial activity against MRSA, 377  
phase 3 study of torezolid phosphate for (PP), 1160  
potential role for complement in immune evasion by *Mycobacterium leprae*, 1373  
retapamulin vs. linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538  
safety and efficacy of CEM-102 vs. linezolid in bacterial skin infections (CTR), 1538  
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285  
TR-701 for bacterial skin infections (CTR), 1538  
using off-patent antibiotics for MRSA (CTR), 1538
- Inflammation**  
anti-inflammatory effects of topical dapsone for acne, 667  
effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330  
multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234  
properties of benzoyl peroxide, 482  
thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814  
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41
- Infliximab**  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
drug-associated acne and acneiform eruptions, 627  
how and when to use biologics in psoriasis, s106 (August)  
rapid improvement of pyoderma gangrenosum after treatment with (CR), 702  
use in pediatric psoriasis, 975
- Ingenol mebutate gel**, for actinic keratoses, s45 (May)
- Insulin injections**, cutaneous nontuberculous mycobacterial abscesses associated with (CR), 1439
- Integra**. See Collagen-glycosaminoglycan copolymer
- Intense pulsed light**, current guide to laser and light-based therapies for acne, 614
- Interferon**  
Helix BioPharma and topical interferon alpha-2b for anogenital warts (PP), 723  
interferon-alpha for infantile hemangiomas (NVR), 176  
intralesional interferon alfa-2b for BCC of nasal pyramid, 381  
medical and surgical management of keloids, 1249  
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883  
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- Interleukin-6**, effect of thalidomide on nitric oxide production in RAW 264.7 cells, 330
- Interleukin-12/23 inhibitors**  
how and when to use biologics in psoriasis, s106 (August)  
for psoriasis and psoriatic arthritis, 947
- Internet**  
sales of isotretinoin (PP), 282  
Sciton launches Japanese language website (PP), 1160
- Intrahepatic cholestasis of pregnancy** (NVR), 1297
- Intrauterine devices**, drug-associated acne and acneiform eruptions, 627
- Intravenous immunoglobulin (IVIG)**  
with or without cyclophosphamide in pemphigus (CTR), 1289  
for scleromyxedema (CR), 263
- Ipilimumab**  
for metastatic melanoma (PP), 1160  
in young patients with advanced or refractory solid tumors (CTR), 883
- Iraq**, prevalence of skin disease in deployed dermatology clinic in, 210
- Iressa®**. See Gefitinib

**Iron overload and cutaneous disease** (NVR), 719  
**Isoniazid**, drug-associated acne and acneiform eruptions, 627  
**Isotretinoin**  
 AADA calls for FDA to address Internet sales of (PP), 282  
 effects of mast cells on wound healing induced by, 1207  
 inflammatory bowel disease and (NVR), 278  
 as monotherapy for sebaceous hyperplasia (CR), 699  
 trends in use for acne vulgaris, 519  
**Istodax**<sup>®</sup>. See Romidepsin  
**Itraconazole**  
 comparison of SUBA™-itraconazole with SPO-RANOX<sup>®</sup> for onychomycosis (CTR), 187, 285, 425  
 efficacy in BCC (CTR), 883, 1035

**J**  
**JC virus infection**, progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005

**Juvederm**  
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Juvéderm<sup>®</sup> XC with lidocaine (PP), 418

**K**  
**Kalbitor**. See Ecallantide  
**Keloids**  
 collagen-glycosaminoglycan copolymer for severe chest keloids, 542  
 evidence-based appraisal of lasers for scars, 1355  
 medical and surgical management of, 1249  
 tolerability and efficacy of two topical therapies for, 514

**Keratinocytes**  
 efficacy of hexapeptide-7 on menopausal skin, 49  
 porokeratosis in patient with hepatitis of unclear etiology (CR), 258  
**Keratoacanthomas**, 117  
**Kineret**. See Anakinra

**L**  
**Lac-Hydrin<sup>®</sup> cream**. See Ammonium lactate  
**Lamotrigine**, drug-associated acne and acneiform eruptions, 627  
**Laser technology**  
 ablative fractional treatment of mature burn scars (CR), 389  
 appearance of burn scar after CO2 fractional laser treatment (CTR), 727  
 combination therapy for rosacea (CTR), 187, 285, 425, 1538  
 comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289  
 comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229  
 current guide to laser and light-based therapies for acne, 614  
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387  
 effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155  
 effects of pulsed-dye laser on scar formation (CTR), 727, 1155

evidence-based appraisal of lasers for scars, 1355  
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK (PP), 1552  
 first fractional laser FDA cleared for stretch marks (PP), 418  
 fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66  
 Groove Optic™ for Lux2940™ for fractional skin resurfacing (PP), 183  
 Hairmax Lasercomb for androgenetic alopecia in females (CTR), 1446  
 laser lipolysis/lipolysis with 980 nm diode laser, s58 (May)  
 laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155  
 medical and surgical management of keloids, 1249  
 multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035  
 Nd:YAG laser for acne keloidalis nuchae (CTR), 569  
 new SkinMedica ablative post-procedure kit (PP), 418  
 onychomycosis therapy, 1109  
 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16  
 pulsed dual-wavelength 595 and 1064 nm in management of hemangiomas, 310  
 pulsed dye laser for infantile hemangiomas (NVR), 176  
 Sciton launches better safety and more efficacy at annual meeting (PP), 418  
 single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341  
 SmartLipo Triplex™ for liposuction (PP), 80  
 Solta Medical to buy Aesthera Corp. (PP), 418  
 “tattoo blow-out” pigment spread treated with QS-Nd:YAG laser (CR), 1429  
 tattoo treatment with alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam, 1333  
 treating onychomycosis (CTR), 187, 425, 1538  
 treatment of androgenetic alopecia in females, 12  
 beam (CTR), 1446  
 treatment of burn scar with CO2 fractional laser (CR), 173  
 treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420  
 treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315  
 treatment of surgical scars with pulsed dye laser (CTR), 727  
 ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328  
 Zerona now FDA-approved for body slimming (PP), 1455  
**Latanoprost**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289  
**Latex sensitivity**, sublingual immunotherapy against (PP), 183  
**LDE225**, safety, local tolerability, pharmacokinetics, and pharmacodynamics on sporadic superficial skin BCC (CTR), 285, 883, 1035  
**Leech therapy**, in cutaneous surgery and disease (CR), 252  
**Leiomyosarcoma**, gemcitabine and docetaxel with or without bevacizumab in 1 malignant fibrous histiocytoma, angiosarcoma and (CTR), 285

**Lenalidomide**  
 for generalized necrobiotic xanthogranuloma (CR), 273  
 for mycosis fungoides/Sézary syndrome (CTR), 883  
**Leprosy**, potential role for complement in immune evasion by *Mycobacterium leprae*, 1373  
**LEQ506**, dose finding and safety study in patients with advanced solid tumors (CTR), 883  
**Letter from the Guest Editor**, 104  
**Letters to the Editor**, 602, 750, 751, 1059, 1475  
**Leukemia**, dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883  
**Levetiracetam**, reticulated drug eruption induced by (CR), 409  
**Levocetirizine**  
 for chronic idiopathic urticaria, 503  
 for pruritus in atopic dermatitis (CTR), 82  
**Levodopa**, phase 1 study of ND0611 dermal patch (PP), 1033  
**Levonorgestrel implants**, drug-associated acne and acneiform eruptions, 627  
**Lice**, benzyl alcohol lotion 5% for head lice (PP), 572  
**Lichen planus**  
 apremilast for (CTR), 577, 883  
 cutaneous and mucosal, efficacy of metronidazole for, 1186  
 etanercept in (CTR), 187, 425, 577  
 lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841  
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73  
 of oral mucosa or skin, safety and effectiveness of etanercept for (CTR), 577, 883  
**Lidocaine**  
 effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097  
 Emervel Classic Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Emervel Deep Lidocaine vs. Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Juvéderm<sup>®</sup> XC with (PP), 418  
 pain with Radiesse<sup>®</sup> with lidocaine for nasolabial folds (CTR), 577  
 safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500  
**Light therapy**, current guide to laser and light-based therapies for acne, 614  
**Linezolid**  
 versus CEM-102 in bacterial skin infections (CTR), 1538  
 versus retapamulin in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538  
**Lip**  
 lip tenting technique for augmentation of, 559  
 PDT to treat actinic damage in patients with SCC of (CTR), 82, 1289  
**Lipoatrophy**, monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipoatrophy in HIV-infected patients (CR), 690  
**Lipodissolve**, FDA warning letters about claims regarding (PP), 874  
**Lipolysis**  
 with 980 nm diode laser, s58 (May)  
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387  
**Lipomas**, dual-wavelength laser lipolysis treatment of (CR), 387  
**Liposuction**, SmartLipo Triplex™ for (PP), 80  
**Lithium**, drug-associated acne and acneiform

- eruptions, 627
- Loratadine**, for chronic idiopathic urticaria, 503
- Lovastatin**, novel treatment for syndromic ichthyoses (CTR), 1155
- Luliconazole solution**, pharmacokinetics and safety in distal subungual onychomycosis (CTR), 577, 1155
- Lumigan**. See Bimatoprost
- Lupus erythematosus**  
cutaneous  
anti-TNF- $\alpha$  therapy and (CR), 1283  
development associated with use of imiquimod to treat AK (CR), 1022  
in pregnancy (NVR), 1297  
safety and efficacy of etanercept for (CTR), 1538  
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in (CTR), 1538  
thalidomide and analogues for, 814  
generalized systemic, atacept in (CTR), 1538
- Lymph nodes**  
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727  
discussing sentinel lymph node biopsy with melanoma patients, 790
- M**
- Macular hypomelanosis**, in pregnant African American woman with toxic nodular goiter (CR), 393
- MAGE-A3 antigen-specific cancer immunotherapeutic**, in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- Magnetic resonance imaging**, progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005
- Malignant fibrous histiocytoma**, gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, angiosarcoma and (CTR), 285
- Malignant proliferating trichilemmal tumor**, utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149
- Mast cells**, isotretinoin-induced effects on wound healing, 1207
- Mederma**<sup>®</sup>, for stretch marks (PP), 418
- Medications in pregnancy** (NVR), 1297
- Melanoma**  
Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164  
complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727  
CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432  
discussing sentinel lymph node biopsy with melanoma patients, 790  
GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289  
MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289  
metastatic  
ipilimumab for (PP), 1160  
promising results of phase 1 trial of PLX4032 (PP), 1455  
Mohs surgery for melanoma in situ, 786  
multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035  
N-acetylcysteine to reduce risk of (PP), 183  
new melanoma staging system (NVR), 1029  
nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883  
osteoinvasive subungual (CR), 159  
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289  
in pregnancy (NVR), 1297  
TH17 in regression of metastatic melanoma to topical diphenycprone, 1368  
thalidomide and analogues for, 814  
unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841  
UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289  
vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
- Melasma**  
azelaic acid vs. hydroquinone in (CTR), 727  
tolerability and efficacy of novel formulation in treatment of, 215  
treatment with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315
- Meningococemia** (NVR), 1545
- Mercury skin lightening cream**, FDA investigation of (PP), 1160
- Merkel cell carcinoma**, 779  
management with emphasis on small primary tumors, 105
- Metformin**, in treatment of acne (NVR), 569
- Methotrexate**  
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82  
in treatment of morphea, 1213
- Methylaminolevulinate (MAL)**  
PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425  
PDT with MAL without occlusion for acne vulgaris, 1347
- 4-Methylbenzylidene camphor**, sunscreen update: controversies, what's safe, what's next (NVR), 1451
- Metronidazole**  
efficacy in treatment of cutaneous and mucosal lichen planus, 1186  
efficacy of topical azelaic acid gel plus oral doxycycline vs. metronidazole gel plus oral doxycycline in rosacea, 607
- MGA031 (teplizumab)**, safety in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577
- Military personnel**, prevalence of skin disease in deployed dermatology clinic in Iraq, 210
- Minocycline**  
acne relapse rate of oral minocycline vs. oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727  
efficacy and safety of doxycycline and minocycline for acne, 1407
- Minoxidil**  
for female pattern hair loss (CTR), 1446  
vs. spironolactone pills in female pattern hair loss (CTR), 577
- Mohs micrographic surgery**  
comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after, 137  
flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268  
fractional photothermolysis for depressed alar scar following (CR), 66  
immunostains used, 760  
for melanoma in situ, 786
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143  
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878  
utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149
- Moisturizers**  
controlled multi-center study evaluating the efficacy of Vivate Skin Care for photoaging of face, eye and mouth, 22  
and cosmeceuticals in clinical practice, s62 (May)  
dapsona gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33  
long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647
- Mometasone furoate**, FDA approval of topical solution USP, 0.1% (PP), 1455
- Morphea**, treatment of, 1213
- Mortality risk**, tigecycline-associated (PP), 1455
- Multi-wavelength and coherence confocal reflectance microscopy**, of pigmented and nonpigmented skin lesions (CTR), 1035
- Mycobacterial infection**  
cutaneous nontuberculous mycobacterial abscesses associated with insulin injections (CR), 1439  
drug therapy for *M. ulcerans* infection, 341  
potential role for complement in immune evasion by *M. leprae*, 1373
- Mycophenolate mofetil**, for chronic dermatitis, 356
- Mycosis fungoides/Sézary syndrome**  
alemtuzumab followed by peripheral stem cell transplantation in (CTR), 883  
development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014  
lenalidomide for (CTR), 883  
PEG-interferon alfa-2b and UV light therapy in (CTR), 883  
study of human monoclonal antibody zanolimumab for (CTR), 883
- N**
- NAB001**, safety and efficacy for onychomycosis of toenails (CTR), 1538
- Nail disorders**  
antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525  
comparison of SUBA<sup>™</sup>-itraconazole with SPO-RANOX<sup>®</sup> for onychomycosis (CTR), 187, 285, 425  
delayed onychodystrophy of incontinentia pigmenti, 350  
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155  
light therapy for toenail fungus (CTR), 285, 577, 1155  
onychomycosis therapy, 1109  
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155  
rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713  
safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538  
safety and efficacy of topical IDP-108 vs. vehicle in onychomycosis (CTR), 285, 577, 1538  
study of effects of increasing doses of drug for

nail fungus (CTR), 187, 425  
 TDT 067 onychomycosis study (CTR), 1538  
 treating onychomycosis (CTR), 187, 425, 1538  
**Nalfurafine HCl (AC-820)**, safety and efficacy in subjects on hemodialysis with uremic pruritus (CTR), 82  
**Nanotechnology**  
 dermal effects of nanoparticles, 475  
 nanotechnology and the Nanodermatology Society (IC), 879  
 sunscreen update: controversies, what's safe, what's next (NVR), 1451  
 as topical therapeutic strategy for vascular dysfunction (RR), 574  
**Neck and face revitalization**, with platelet-rich plasma, 466  
**Necrobiotic xanthogranuloma**, generalized, lenalidomide for (CR), 273  
**Necrotizing fasciitis**, drug therapy for, 341  
**Necrotizing vasculitis**, drug therapy for, 341  
**Neoplasia**  
 ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82  
 alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 883  
 bevacizumab for angiosarcoma (CTR), 285  
 bimatoprost ophthalmic solution in promoting eyebrow and eyelash hair growth in breast cancer patients (CTR), 82, 577  
 BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1035  
 celecoxib inhibition of genetic BCC (PP), 418  
 Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164  
 complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727  
 correlation between skin carotenoid levels and previous history of skin cancer (CTR), 1289  
 CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432  
 current treatments for infantile hemangiomas (NVR), 176  
 dasatinib for unresectable or metastatic SCC (CTR), 285  
 dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883  
 dermoscopy impact on skin cancer diagnostics, 129  
 development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014  
 discussing sentinel lymph node biopsy with melanoma patients, 790  
 dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883  
 dual-wavelength laser lipolysis treatment of lipomas (CR), 387  
 efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285  
 efficacy of itraconazole in BCC (CTR), 883, 1035  
 efficacy of PDT for recurrent SCC and BCC, 122  
 electrocauterization and curettage vs. excision for SCC, 773  
 electronic brachytherapy for non-melanoma skin cancer (CTR), 1035  
 erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285  
 erlotinib in women with SCC of vulva (CTR), 1289

erlotinib prior to surgery of radiation in patients with SCC (CTR), 883  
 flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268  
 gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285  
 GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289  
 human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 883  
 intralesional interferon alfa-2b for BCC of nasal pyramid, 381  
 ipilimumab for metastatic melanoma (PP), 1160  
 ipilimumab in young patients with advanced or refractory solid tumors (CTR), 883  
 Istdox for cutaneous T-cell lymphoma (PP), 183  
 keratoacanthomas, 117  
 lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 883  
 MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289  
 management of Merkel cell carcinoma with emphasis on small primary tumors, 105  
 Merkel cell carcinoma, 779  
 Mohs surgery for melanoma in situ, 786  
 multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152  
 multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1035  
 N-acetylcysteine to reduce melanoma risk (PP), 183  
 new melanoma staging system (NVR), 1029  
 nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883  
 non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277  
 osteoinvasive subungual melanoma (CR), 159  
 patient with nevoid BCC syndrome treated successfully with PDT (CR), 167  
 PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289  
 PDT using ALA in treating patients with skin cancer (CTR), 82  
 PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883  
 pegylated interferon for children with high-risk melanoma (CTR), 727, 1289  
 population education in preventing skin cancer: from childhood to adulthood, 112  
 in pregnancy (NVR), 1297  
 promising results of metastatic melanoma phase 1 trial of PLX4032 (PP), 1455  
 rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143  
 rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878  
 role of phototherapy in cutaneous T-cell lymphoma, 764  
 maintenance phototherapy, 800  
 safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035  
 sorafenib-induced psoriasiform eruption in

patient with metastatic thyroid carcinoma (CR), 169  
 successful treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017  
 systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753  
 TH17 in regression of metastatic melanoma to topical diphencyprone, 1368  
 thalidomide and analogues for immunomodulation of inflammatory and neoplastic disorders, 814  
 trial of Dermacorder for detecting malignant skin lesions (CTR), 883  
 UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289  
 vaccine therapy in stage IV cutaneous melanoma (CTR), 1289  
 ZD1839 for recurrent or metastatic SCC of skin (CTR), 883  
**Nephrogenic systemic fibrosis**, 829  
**News, Views, and Reviews (NVR)**, 76, 176, 278, 412, 569, 719, 871, 1029, 1297, 1451, 1545  
**Niacinamide**, cosmeceuticals in clinical practice, s62 (May)  
**Nigerian plants**, for cancer-related alopecia, 537  
**Nilotinib**, in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883  
**Nitric oxide**, effect of thalidomide on production in RAW 264.7 cells, 330

## O

**Ocular cicatricial pemphigoid**  
 etanercept for (CR), 68  
 rituximab in (CTR), 187, 425, 577, 1289  
**Omalizumab**, efficacy and safety in bullous pemphigoid (CTR), 187, 425, 577, 1289  
**Onion extract gel**, for keloids and hypertrophic scars, 514  
**Onion juice**, for alopecia, 537  
**Onychodystrophy**, delayed, of incontinentia pigmenti, 350  
**Onychomycosis**  
 antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525  
 comparison of SUBA™-itraconazole with SPO-RANOX® for (CTR), 187, 285, 425  
 efficacy and safety of iontophoretic application of terbinafine gel in (CTR), 577, 1155  
 light therapy for (CTR), 285, 577, 1155  
 pharmacokinetics and safety of luliconazole solution in (CTR), 577, 1155  
 safety and efficacy of NAB001 for onychomycosis of toenails (CTR), 1538  
 safety and efficacy of topical IDP-108 vs. vehicle in (CTR), 285, 577, 1538  
 study of effects of increasing doses of drug for nail fungus (CTR), 187, 425  
 TDT 067 study (CTR), 1538  
 therapy for, 1109  
 treatment of (CTR), 187, 425, 1538  
**Oral contraceptives**, trends in use for acne vulgaris, 519  
**Oral lesions**  
 etanercept for recalcitrant cicatricial pemphigoid (CR), 68  
 oral glutamine to suppress recurrent herpes labialis (CTR), 285  
 oral lichenoid drug reaction associated with anti-hypertensive and hypoglycemic drugs (CR), 73  
 retinoids for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151

- safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883
- safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285
- Oregano-based ointment**, with antimicrobial activity against MRSA, 377
- Oseltamivir** (NVR), 76
- Osteoinvasive subungual melanoma** (CR), 159
- Oxandrolone**, in treatment of decubitus ulcers (CR), 711
- Oxidative stress**  
dose-dependent antioxidant function of resveratrol, 1523  
efficacy and tolerance of novel phenolic antioxidant skin care system, 1480  
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11
- Oxybenzone**, sunscreen update: controversies, what's safe, what's next (NVR), 1451
- P**
- P-3051**, antifungal activity and nail permeation of innovative ciclopirox nail lacquer, 525
- Pain**, with Radiesse® with lidocaine for nasolabial folds (CTR), 577
- Palmoplantar keratoderma**, efficacy and safety of topical keratolytic treatment for, 1512
- Palmyitoyethanolamide-containing cream**, for atopic dermatitis, 334
- Pancreatitis, panniculitis and polyarthritis syndrome** (CR), 1145
- Panicum miliaceum, for cancer-related alopecia, 537
- Panitumumab**, cutaneous reactions to epidermal growth factor receptor inhibitors, 1229
- Paraffin**, histopathologic identification of dermal filler agents, 1072
- Parasitosis, delusions of**, aripiprazole for (CR), 1531
- Parkinson's disease**, phase 1 study of ND0611 dermal patch (PP), 1033
- Patient education**, approaching psoriasis: patient-physician relationships, patient education and choosing the right topical vehicle, 908
- Pediatric dermatology**  
corticosteroids for infantile hemangiomas impair immune function (PP), 1033  
current treatments for infantile hemangiomas (NVR), 176  
dermatologic indicators of eating disorders (NVR), 412  
Epiduo® pediatric acne study (CTR), 1155  
novel treatment for syndromic ichthyoses (CTR), 1155  
pediatric indication for Locoid Lipocream® cream (PP), 80  
pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446  
pegylated interferon for children with high-risk melanoma (CTR), 727, 1289  
population education in preventing skin cancer: from childhood to adulthood, 112  
pulsed dual-wavelength 595 and 1064 nm in management of hemangiomas, 310  
rapid improvement in digital ischemia and acral contracture in collodion baby treated with topical tazarotene (CR), 713  
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285  
topical tretinoin gel and acne in preadolescents (PP), 1033
- topical vitamin B12 for childhood atopic dermatitis (CTR), 1155, 1446
- use of biologic agents in pediatric psoriasis, 975
- voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
- PEG-interferon alfa-2b**, and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883
- Pemphigoid**  
bullous, efficacy and safety of omalizumab in (CTR), 187, 425, 577, 1289  
etanercept for recalcitrant cicatricial pemphigoid (CR), 68  
rituximab in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289
- Pemphigus vulgaris**  
IVIg with or without cyclophosphamide in (CTR), 1289  
pimecrolimus cream for cutaneous lesions of, 684
- Perilyl alcohol, topical**, in treating patients with sun damaged skin and AK (CTR), 82
- Perioral region**, injection techniques for revolumization with hyaluronic acid, 367
- Periorbital region**  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289  
minimally invasive techniques for periorbital rejuvenation, s118 (August)  
novel sonic infusion system for periorbital rhytides, 1121  
prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16
- Peripheral artery disease**  
combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289  
safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289
- Pemiosis**, successful treatment with hydroxychloroquine, 1242
- Pharmacokinetics**  
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285  
safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446  
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1035  
and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155
- Phosphodiesterase-4 inhibitor**, safety study of clinical and immune effects in cutaneous lupus (CTR), 1538
- Photoaging**. See also Cutaneous aging  
comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1035, 1155, 1289  
controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
efficacy and tolerance of novel phenolic antioxidant skin care system for, 1480  
MyoScience Tissue Remodeling Device for facial rejuvenation (CTR), 577  
Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187  
topical perilyl alcohol in treating patients with sun damaged skin and AK (CTR), 82
- topically dissolved oxygen (TDO) to ameliorate signs of photodamage (CTR), 187, 425
- treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220
- voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
- Photodynamic therapy (PDT)**  
for actinic keratoses, s45 (May)  
ALA-PDT for cutaneous pseudolymphoma (CR), 688  
ALA-PDT vs. vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82  
comparison of safety and efficacy of ALA plus a 532 nm KTP laser vs. 532 nm KTP laser alone for facial acne, 229  
current guide to laser and light-based therapies for acne, 614  
efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446  
efficacy for recurrent SCC and BCC, 122  
patient with nevoid BCC syndrome treated successfully with (CR), 167  
PDT with MAL cream in patients with skin type V or IV with acne (CTR), 187, 425  
PDT with MAL without occlusion for acne vulgaris, 1347  
rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143  
rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878  
to treat actinic damage in patients with SCC of lip (CTR), 82, 1289  
in treatment of morphea, 1213  
using ALA in treating patients with skin cancer (CTR), 82  
utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864
- Photopneumatic technology**, stratum corneum permeation and percutaneous drug delivery of hydrophilic molecules enhanced by, 1528
- Photosensitivity**, voriconazole-induced photosensitivity/photoaging in X-linked chronic granulomatous disease (CR), 562
- Phototherapy**  
current guide to laser and light-based therapies for acne, 614  
light therapy to treat toe nail fungus (CTR), 285, 577, 1155  
PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 883  
role in cutaneous T-cell lymphoma, 764  
for toenail fungus (CTR), 285, 577  
in treatment of morphea, 1213  
usefulness of narrowband UVB as monotherapy for chronic plaque psoriasis, 989
- Pigmentation**  
azelaic acid vs. hydroquinone in melasma (CTR), 727  
effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289  
failure of botulinum toxin treatment for localized vitiligo, 1092  
localized argyria secondary to acupuncture (CR), 1019  
macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393

pimecrolimus for idiopathic guttate hypomelanosis (BC), 238  
 tolerability and efficacy of novel formulation in treatment of melasma, 215  
 treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420  
 treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or combination of the two, 315  
 unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma (CR), 841

**Pimecrolimus**  
 cost-effectiveness vs. tacrolimus ointment for atopic dermatitis, 372  
 for cutaneous lesions of pemphigus vulgaris, 684  
 effect on cathelicidin levels in eczema (CTR), 883  
 for idiopathic guttate hypomelanosis (BC), 238  
 versus tacrolimus for pruritus in atopic dermatitis, 488

**Pipeline Previews (PP)**  
 AADA calls for FDA to address Internet sales of isotretinoin, 282  
 AADA endorses Senate's proposed indoor tanning tax, 282  
 AccuView digital imaging system, 418  
 antioxidant N-acetylcysteine to reduce melanoma risk, 183  
 Belotero dermal filler close to FDA approval, 1455  
 benzoyl peroxide-clindamycin combinations and skin hydration, 80  
 benzyl alcohol lotion 5% for head lice, 572  
 Biopelle secures rights to distribute Heliocare®, 183  
 botulinum toxin type A reduces itch, 282  
 Canfield introduces new facial 3D imaging system, 418  
 celecoxib inhibition of genetic BCC, 418  
 Clinuvel Pharmaceuticals gets FDA approval for light intolerance drug trial, 723  
 corticosteroids for infantile hemangiomas impair immune function, 1033  
 efalizumab for resistant plaque psoriasis, 183  
 Ertaczo® relieves itching, 80  
 FDA 510(k) clearance of Fraxel re:store Dual Laser for AK, 1552  
 FDA Advisory Committee recommends approval of ceftaroline fosamil, 1552  
 FDA approval of ecallantide for hereditary angioedema, 572  
 FDA approval of e-Matrix device, 572  
 FDA approval of Istodax for cutaneous T-cell lymphoma, 183  
 FDA approval of mometasone furoate topical solution USP, 0.1%, 1455  
 Fda approves Exilis body shaping as nonsurgical device, 874  
 FDA approves Glenmark's calcipotriene ointment, 723  
 FDA approves Juvéderm® XC with lidocaine, 418  
 FDA approves Merz Pharmaceuticals' Xeomin®, 1455  
 FDA approves new indications for HPV vaccine, 80  
 FDA approves polidocanol for small varicose veins, 723  
 FDA approves Qutenza® for postherpetic neuralgia, 282  
 FDA approves Ulthera's ultrasound product, 282  
 FDA approves Zyclara™, 723  
 FDA clearance of V.A.C. therapy for venous insufficiency ulcers, 1160  
 FDA issues warning letters about claims regarding lipodissolve, 874  
 FDA panel makes tanning bed recommendations,

874  
 FDA reviewing safety of antibacterial soap ingredient triclosan, 874  
 FDA warns consumers in Puerto Rico of harmful bacteria in hand sanitizers, 874  
 FDA widens mercury skin lightening cream investigation, 1160  
 first fractional laser FDA cleared for stretch marks, 418  
 Galderma receives approval for Differin® (adapalene) lotion 0.1%, 723  
 generic approval of adapalene cream 0.1%, 1160  
 generic approval of imiquimod cream 5%, 572  
 Groove Optic™ for Lux2940™ for fractional skin resurfacing, 183  
 Helix BioPharma and topical interferon alpha-2b, 723  
 high resolution ultrasound helps in diagnosis of blue skin lesions, 1160  
 imatinib in scleroderma, 80  
 ipilimumab for metastatic melanoma, 1160  
 Iredale Mineral Cosmetics receives Seal of Recommendation from Skin Cancer Foundation, 572  
 Mederma® for stretch marks, 418  
 Mylan receives approval for generic Valtrex®, 1033  
 Mylan receives approval for hydroxyzine hydrochloride tablets, 1160  
 new SkinMedica ablative post-procedure kit, 418  
 new study implicates autoimmune mechanisms in alopecia areata, 1160  
 pediatric indication for Locoid Lipocream® cream, 80  
 Perrigo announces FDA approval for imiquimod cream, 1552  
 phase 1 study of ND0611 dermal patch, 1033  
 positive phase 2b clinical trial of psoriasis drug apremilast, 282  
 promising results of metastatic melanoma phase 1 trial of PLX4032, 1455  
 prompt biological therapy speeds diabetic foot ulcer healing, 1455  
 PureGraft™ System receives marketing clearance, 723  
 sales of Basilea's antibiotic Zeftera stopped in Canada, 874  
 Sanofi Pasteur and Syntiron, 282  
 Sciton launches better safety and more efficacy at annual meeting, 418  
 Sciton launches Japanese language website to enhance customer experience, 1160  
 SkinMedical launches new Rejuvenize Peel™, 418  
 SmartLipo Triplex™ for liposuction, 80  
 Soligenix study of orBec® for prevention of GVHD (PP), 1033  
 Solta Medical to buy Aesthera Corp., 418  
 Stelara (ustekinumab) vs. etanercept for psoriasis, 572  
 tigecycline linked to increased mortality risk, 1455  
 topical tretinoin gel and acne in preadolescents, 1033  
 Trius Therapeutics phase 3 study of torezolid phosphate, 1160  
 Zeltiq receives FDA clearance, 1552  
 Zerona now FDA-approved for body slimming, 1455

**Pityriasis rosea**, management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241  
**Pityriasis rubra pilaris**, familial (CR), 844  
**Platelet-rich plasma (PRP)**, face and neck revitalization with, 466  
**PLX4032**, promising results of metastatic melanoma phase 1 trial (PP), 1455

**Polidocanol**  
 approval for sclerotherapy (NVR), 871  
 FDA approval for small varicose veins (PP), 723

**Poly-L-lactic acid (PLLA)**  
 fillers for facial shaping, s129 (August)  
 histopathologic identification of dermal filler agents, 1072  
 use in people of color, 451

**Polymethylmethacrylate/bovine collagen**, histopathologic identification of dermal filler agents, 1072

**Polymethylmethacrylate/carboxyglucuronate**, histopathologic identification of dermal filler agents, 1072

**Population education**, in preventing skin cancer: from childhood to adulthood, 112

**Porokeratosis**, in patient with hepatitis of unclear etiology (CR), 258

**Porphyria cutanea tarda** (NVR), 719

**Postherpetic neuralgia**, FDA approves Qutenza® for (PP), 282

**Potassium titanyl phosphate laser**, current guide to laser and light-based therapies for acne, 614

**Pregnancy**  
 dermatology in (NVR), 1297  
 macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393

**Pressure ulcers**, oxandrolone treatment of (CR), 711

**Prevention**  
 ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82  
 population education in preventing skin cancer: from childhood to adulthood, 112  
 Soligenix study of orBec® for prevention of GVHD (PP), 1033  
 systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753  
 topical cidofovir for prevention of hair growth (CTR), 82

**Primula**, for alopecia, 537

**PRK 124 lotion**, long-term efficacy and safety in rosacea, 647

**Procyanidins**, for alopecia, 537

**Progressive multifocal leukoencephalopathy**, in two psoriasis patients treated with efalizumab (CR), 1005

**Propranolol**, for infantile hemangiomas (NVR), 176

**Prostaglandin eye drops**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

**Protopic®**, pediatric longitudinal evaluation of long-term safety for atopic dermatitis (CTR), 1446

**Provenge (Sipuleucel-T)**, role of complement in dendritic cell control of T-cell subsets (editorial), 1364

**Prurigo of pregnancy** (NVR), 1297

**Pruritic folliculitis of pregnancy** (NVR), 1297

**Pruritus**  
 in atopic dermatitis, 488  
 botulinum toxin type A reduces itch (PP), 282  
 efficacy of topical antihistamines for, 992  
 Ertaczo® for (PP), 80  
 management with Xyzal in atopic dermatitis (CTR), 82  
 in pregnancy (NVR), 1297  
 safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82

**Psoralen-UVA**, drug-associated acne and acneiform eruptions, 627

### Psoriasis

AIN457 regimen finding study in (CTR), 285  
alefacept treatment for up to one year, 1491  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
bicillin LA versus placebo for psoriasis unresponsive to topical medications (CTR), 425  
botulinum toxin for (CTR), 82, 1033  
bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation (CR), 1010  
clinical activity, safety, and tolerability of SRT2104 in subjects with (CTR), 1446  
dose finding study of AEB071 assessing psoriasis area and severity index in patients with (CTR), 285  
efalizumab for resistant plaque (PP), 183  
efficacy and safety of adding methotrexate to etanercept in (CTR), 82  
efficacy and safety of ASP015K in (CTR), 1033, 1446  
efficacy of 15% azelaic acid in, 964  
efficacy of Ultravate ointment in combination with Lac-Hydrin cream for (CTR), 285, 577, 1033  
erlotinib for (CTR), 82, 187, 285, 425, 577, 1033, 1446  
evaluation of single dose of ILV-095 in subjects with (CTR), 285, 577, 1033, 1446  
evidence-based review of coal tar preparations for, 1258  
FDA approves Glenmark's calcipotriene ointment for (PP), 723  
fluphenazine hydrochloride for (CTR), 187, 425, 1446  
how and when to use biologics in, s106 (August)  
injectable biologic and U0279 combination therapy for (CTR), 285  
long-term safety and efficacy of etanercept in, 928  
management of guttate psoriasis and pityriasis rosea in patients with evidence of group A streptococcal infection (CR), 241  
non-Hodgkin's B-cell lymphoma in a psoriatic patient (CR), 1277  
patient-physician relationships, patient education and choosing the right topical vehicle, 908  
positive phase 2b clinical trial of apremilast for (PP), 282  
in pregnancy (NVR), 1297  
progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab (CR), 1005  
prospective new biologic therapies for psoriatic arthritis and, 947  
safety and efficacy of BFH772 in patients with (CTR), 187, 425  
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for, 969  
safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577  
scalp, 912, s101 (August)  
thalidomide and analogues for, 814  
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41  
treatment in alcoholics (CR), 405  
treatment patterns and perceptions of treatment attributes, satisfaction and effectiveness among patients with, 938  
use of biologic agents in pediatric patients with, 975  
usefulness of narrowband UVB as monotherapy

for chronic plaque psoriasis, 989  
ustekinumab versus etanercept for (PP), 572  
VB-201 for (CTR), 1033, 1446  
**Psoriatic arthritis**  
adult onset, certolizumab pegol for (CTR), 1446  
atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy (CR), 57  
prospective new biologic therapies for psoriasis and, 947  
safety and efficacy of ustekinumab in patients who have prior exposure to anti-TNF agents (CTR), 1155  
**Psychosocial sequelae of acne**, s50 (May)  
**Pulsed dye laser**  
combination therapy for rosacea (CTR), 187, 285, 425, 1538  
current guide to laser and light-based therapies for acne, 614  
effect on scar formation (CTR), 1155  
for infantile hemangiomas (NVR), 176  
treatment of surgical scars with (CTR), 727  
**Purging behavior**, dermatologic indicators of (NVR), 412  
**Purpura fulminans**, drug therapy for, 341  
**Pycnogenol**, oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11  
**Pyoderma gangrenosum**, drug therapy for, 341  
**Pyoderma gangrenosum**, rapid improvement after infliximab treatment (CR), 702  
**Pyratine-XR**. See PRK 124 lotion

## Q

**Quinidine**, drug-associated acne and acneiform eruptions, 627  
**Qutenza®**. See Capsaicin

## R

**Race/ethnicity**  
attaining predictable aesthetic results with dermal fillers, 458  
macular hypomelanosis in pregnant African American woman with toxic nodular goiter (CR), 393  
use of injectable poly-L-lactic acid in people of color, 451  
**Radiation therapy**  
and erlotinib for cutaneous SCC (CTR), 82, 285  
erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289  
medical and surgical management of keloids, 1249  
**Radiesse®**. See Calcium hydroxylapatite  
**Raspberry ketone**, for alopecia, 537  
**Red man syndrome** (NVR), 76  
**Rejuvenize Peel™** (PP), 418  
**Relaxation strategies**, for patients during dermatologic surgery, 795  
**Remicade®**. See Infliximab  
**Renal disease**  
drug therapy for calciphylaxis, 341  
nephrogenic systemic fibrosis, 829  
safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82  
warfarin-induced skin necrosis mimicking calciphylaxis (CR), 859  
**Resident Rounds**, 574, 725, 878  
**Restasis**. See Cyclosporin ophthalmic solution  
**Restylane**. See Hyaluronic acid  
**Resveratrol**, dose-dependent antioxidant function of, 1523

### Retapamulin

in age of *S. aureus* antimicrobial resistance, 1198  
versus linezolid in treatment of SITL and impetigo due to MRSA (CTR), 82, 1538  
treatment of atopic dermatitis with concurrent Altabax® and topical low-potency corticosteroids versus low-potency corticosteroid monotherapy (CTR), 883, 1033

### Retinoids

AADA calls for FDA to address Internet sales of isotretinoin (PP), 282  
acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727  
antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131  
Atralin gel for rosacea (CTR), 1033, 1538  
irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 998  
isotretinoin and inflammatory bowel disease and (NVR), 278  
isotretinoin as monotherapy for sebaceous hyperplasia (CR), 699  
isotretinoin-induced effects of mast cells on wound healing, 1207  
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805  
optimizing acne therapy with unique vehicles, s53 (May)  
oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11  
for palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis (CR), 1151  
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033  
sunscreens update: controversies, what's safe, what's next (NVR), 1446  
systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753  
topical tretinoin gel and acne in preadolescents (PP), 1033  
treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and tretinoin, 220  
trends in use for acne vulgaris, 519  
**Rifampicin**, drug-associated acne and acneiform eruptions, 627  
**Rituximab**, in ocular cicatricial pemphigoid (CTR), 187, 425, 577, 1289  
**Rocky Mountain spotted fever** (NVR), 1545  
**Romidepsin**, for cutaneous T-cell lymphoma (PP), 183  
**Rosacea**  
apremilast for (CTR), 727, 1033, 1538  
Atralin gel for (CTR), 1033, 1538  
changes in comorbidities and treatment utilization over time, 1402  
combination therapy for (CTR), 187, 285, 425, 1538  
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with (CTR), 1538  
efficacy of topical azelaic acid gel plus oral doxycycline versus metronidazole gel plus oral doxycycline in, 607  
long-term efficacy and safety of topical PRK 124 lotion for, 647  
safety and efficacy of clindamycin and tretinoin gel for (CTR), 187, 285, 425, 1033, 1538

topical cyclosporin for ocular rosacea (CTR), 285  
we are making progress with acne and rosacea (editorial), 603

## S

### Safety issues

clinical activity, safety, and tolerability of SRT2104 in subjects with psoriasis (CTR), 1446  
comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137  
comparison of safety and efficacy of ALA plus a 532 nm KTP laser versus 532 nm KTP laser alone for facial acne, 229  
dapsona gel in combination with adapalene gel, benzoyl peroxide gel or moisturizer for acne vulgaris, 33  
dose finding and safety study of oral LEQ506 in patients with advanced solid tumors (CTR), 883  
efficacy and safety of adding methotrexate to etanercept in psoriasis (CTR), 82  
efficacy and safety of ASP015K in psoriasis (CTR), 1033, 1446  
efficacy and safety of CD07223 gel in subjects with acne (CTR), 1446  
efficacy and safety of CD07805/47 gel in subjects with facial erythema associated with rosacea (CTR), 1538  
efficacy and safety of doxycycline and minocycline for acne, 1407  
efficacy and safety of fixed-dose adapalene-benzoyl peroxide combination gel for acne in adolescents, 1395  
efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285  
efficacy and safety of iontophoretic application of terbinafine gel in onychomycosis (CTR), 577, 1155  
efficacy and safety of new topical keratolytic treatment for hyperkeratosis, 1512  
efficacy and safety of omalizumab in bullous pemphigoid (CTR), 187, 425, 577, 1289  
efficacy and safety of Visonac PDT for acne (CTR), 1155, 1289, 1446  
efficacy and safety study of 3.75% imiquimod cream following cryosurgery for AK, 1101  
expanding the use of neurotoxins in facial aesthetics, s7 (January)  
FDA reviewing safety of triclosan (PP), 874  
FDA warns consumers in Puerto Rico of harmful bacteria in hand sanitizers (PP), 874  
long-term efficacy and safety of topical PRK 124 lotion for rosacea, 647  
long-term safety and efficacy of etanercept in psoriasis, 928  
morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805  
pediatric longitudinal evaluation of long-term safety of Protopic® for atopic dermatitis (CTR), 1446  
pharmacokinetics and safety of luliconazole solution in distal subungual onychomycosis (CTR), 577, 1155  
phase I study of BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1033  
safety and effectiveness of etanercept for lichen planus of oral mucosa or skin (CTR), 577, 883  
safety and efficacy of abatacept for chronic urticaria after inadequate response to antihistamine therapy (CTR), 82, 1155  
safety and efficacy of BFH772 in psoriasis patients

(CTR), 187, 425  
safety and efficacy of CEM-102 versus linezolid in bacterial skin infections (CTR), 1538  
safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033, 1538  
safety and efficacy of etanercept for discoid lupus erythematosus (CTR), 1538  
safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 727  
safety and efficacy of IDP-107 in patients with acne vulgaris (CTR), 1446  
safety and efficacy of oral nalfurafine HCl (AC-820) in subjects on hemodialysis with uremic pruritus (CTR), 82  
safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549  
safety and efficacy of tazarotene foam 0.1% in subjects with facial acne (CTR), 187, 425, 1446  
safety and efficacy of topical 4% lidocaine gel in unique drug delivery system, 1500  
safety and efficacy of topical IDP-108 versus vehicle in onychomycosis (CTR), 285, 577, 1538  
safety and efficacy of ustekinumab in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155  
safety and HPA axis effects of two-compound ointment containing calcipotriene/betamethasone dipropionate for psoriasis, 969  
safety and pharmacokinetics of famciclovir single 1,500 mg dose in adolescents with recurrent herpes labialis (CTR), 285  
safety and pharmacokinetics of new formulation of bimatoprost in alopecia (CTR), 1446  
safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1033  
safety of dapsona in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients, 532  
safety of teplizumab (MGA031) in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577  
safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96  
safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 883, 1033, 1155, 1446  
safety study of clinical and immune effects of phosphodiesterase-4 inhibitor in cutaneous lupus (CTR), 1538  
tolerability and efficacy of novel formulation in treatment of melasma, 215  
**Sarcoidosis**, thalidomide and analogues for, 814  
**Scalp lesions**  
flexible scalpels for minimally invasive and minimally scarring surgery for large scalp tumors, 1268  
psoriasis, 912, s101 (August)  
therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41  
utilization of a new tissue expander in closure of large Mohs surgical defect (CR), 149  
**Scalpel**  
flexible, for minimally invasive and minimally scarring surgery for large scalp tumors, 1268 modified, in hair restoration, 1266  
**Scars/scarring**  
ablative fractional treatment of mature thermal burn scars (CR), 389  
appearance of burn scar after CO2 fractional laser treatment (CTR), 727  
collagen-glycosaminoglycan copolymer for severe chest keloids, 542

correction of atrophic acne scars with Artefill®, 1062  
effects of fractional carbon dioxide laser treatment prior to wound closure (CTR), 1155  
effects of pulsed-dye laser on scar formation (CTR), 727, 1155  
efficacy of spray silicone in alteration of burn scar (CTR), 727  
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856  
evidence-based appraisal of lasers for scars, 1355  
fractional photothermolysis for depressed alar scar following Mohs micrographic surgery (CR), 66  
laser treatment for fresh surgical scars and mature scars (CTR), 727, 1155  
medical and surgical management of keloids, 1249  
Nd:YAG laser for acne keloidalis nuchae (CTR), 577  
safety and efficacy of EXC 001 to improve appearance of scars from prior breast surgery (CTR), 727  
single-spot, 2940-nm Er:YAG dual-mode laser treatment of facial acne scars, 1341  
tolerability and efficacy of two topical therapies for keloids and hypertrophic scars, 514  
treatment of burn scar with CO2 fractional laser (CR), 173  
treatment of facial atrophic scars with Esthélic, 1507  
treatment of surgical scars with pulsed dye laser (CTR), 727  
ultrapulsed fractional CO2 laser for post-traumatic and pathological scars, 1328  
**Scleroderma**  
imatinib in (PP), 80  
localized, treatment of, 1213  
**Scleromyxedema**, IV immunoglobulin therapy for (CR), 263  
**Sclerotherapy**, FDA approval of polidocanol for (NVR), 871  
**Sculptra®**. See Poly-L-lactic acid  
**Sebaceous hyperplasia**, isotretinoin as monotherapy for (CR), 699  
**Seborrheic dermatitis**, therapeutic shampoos for targeting symptoms of inflammatory scalp disorders, 41  
**Sertaconazole nitrate cream**, for itching (PP), 80  
**Sézary syndrome**. See Mycosis fungoides/Sézary syndrome  
**Shampoos**, therapeutic, for targeting symptoms of inflammatory scalp disorders, 41  
**Sickle cell ulcers**, arginine butyrate plus standard local therapy in patients with (CTR), 1289  
**Siddha medicine**, for cancer-related alopecia, 537  
**Silicone**  
efficacy of spray silicone in alteration of burn scar (CTR), 727  
evaluation of a liquid silicone gel on scar appearance after excisional surgery (CR), 856  
fillers for facial shaping, s129 (August)  
histopathologic identification of dermal filler agents, 1072  
hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514  
**Simvastatin**, hair growth in patients with alopecia areata totalis after treatment with ezetimibe and (CR), 62  
**Sirolimus**, drug-associated acne and acneiform eruptions, 627  
**Skin cancer**  
ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid

- organ transplant recipients (CTR), 82
- alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 888
- bevacizumab for angiosarcoma (CTR), 285
- BMS-833923 (XL139) in advanced or metastatic cancer (CTR), 883, 1033
- celecoxib inhibition of genetic BCC (PP), 418
- Charcot-Marie-Tooth disease and multiple malignant melanomas (CR), 164
- complete lymph node dissection or observation in treating patients with localized melanoma and sentinel node metastasis (CTR), 727
- correlation between skin carotenoid levels and previous history of (CTR), 1289
- CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432
- dasatinib for unresectable or metastatic SCC (CTR), 285
- dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- dermoscopy impact on skin cancer diagnostics, 129
- development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome (CR), 1014
- discussing sentinel lymph node biopsy with melanoma patients, 790
- efficacy and safety of GDC-0449 in patients with advanced BCC (CTR), 82, 285
- efficacy of itraconazole in BCC (CTR), 883, 1033
- efficacy of PDT for recurrent SCC and BCC, 122
- electrodesiccation and curettage versus excision for SCC, 773
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1033
- erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
- erlotinib in women with SCC of vulva (CTR), 1289
- erlotinib prior to surgery or radiation in patients with SCC (CTR), 883, 1289
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- gemcitabine and docetaxel with or without bevacizumab in leiomyosarcoma, malignant fibrous histiocytoma and angiosarcoma (CTR), 285
- GSK2132231A antigen-specific immunotherapeutic in patients with inoperable metastatic cutaneous melanoma (CTR), 727, 1289
- human monoclonal antibody zanolimumab to treat mycosis fungoides/Sézary syndrome (CTR), 888
- immunostains used in Mohs surgery, 760
- intralesional interferon alfa-2b for BCC of nasal pyramid, 381
- ipilimumab for metastatic melanoma (PP), 1160
- iron overload and (NVR), 719
- Istodax for cutaneous T-cell lymphoma (PP), 183
- keratoacanthomas, 117
- lenalidomide for mycosis fungoides/Sézary syndrome (CTR), 888
- MAGE-A3 antigen-specific cancer immunotherapeutic in patients with progressive metastatic cutaneous melanoma (CTR), 1289
- management of Merkel cell carcinoma with emphasis on small primary tumors, 105
- Merkel cell carcinoma, 779
- Mohs surgery for melanoma in situ, 786
- multiple skin cancers in a patient on combination immunosuppressive therapy for Behçet's disease (CR), 152
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
- N-acetylcysteine to reduce melanoma risk (PP), 183
- new melanoma staging system (NVR), 1029
- nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sundamaged melanoma (CTR), 883
- osteoinvasive subungual melanoma (CR), 159
- patient with nevoid BCC syndrome treated successfully with PDT (CR), 167
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- PDT using ALA in treating patients with (CTR), 85
- PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888
- pegylated interferon for children with high-risk melanoma (CTR), 727, 1289
- population education in prevention: from childhood to adulthood, 112
- in pregnancy (NVR), 1297
- promising results of metastatic melanoma phase 1 trial of PLX4032 (PP), 1455
- rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143
- rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878
- role of phototherapy in cutaneous T-cell lymphoma, 764
- maintenance phototherapy, 800
- safety, local tolerability, pharmacokinetics, and pharmacodynamics of LDE225 on sporadic superficial skin BCC (CTR), 285, 883, 1033
- successful treatment of cutaneous T-cell lymphoma with topical 5-fluorouracil (CR), 1017
- systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients, 753
- TH17 in regression of metastatic melanoma to topical diphenylprone, 1368
- thalidomide and analogues for, 814
- trial of Dermacorder for detecting malignant skin lesions (CTR), 883
- UV light exposure and immunosuppression in cutaneous melanoma (CTR), 1289
- vaccine therapy in stage IV cutaneous melanoma (CTR), 1289
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
- Skin Cancer Foundation**, Iredale Mineral Cosmetics receives Seal of Recommendation from, 572
- Skin resurfacing**
- Groove Optic™ for Lux2940™ for (PP), 183
- treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing (CR), 1420
- Sodium sulfacetamide 10%, sulfur emollient 5% foam**, in treatment of inflammatory facial dermatoses (BC), 234
- Soft tissue augmentation**
- attaining predictable aesthetic results with dermal fillers, 458
- Belotero dermal filler close to FDA approval (PP), 1455
- calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446
- Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
- Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538
- fillers for facial shaping, s129 (August)
- hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135
- injection techniques for revolumization of perioral region with hyaluronic acid, 367
- monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipotrophy in HIV-infected patients (CR), 690
- pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577
- Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187
- treatment of facial atrophic scars with Esthéélis, 1507
- treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538
- use of injectable poly-L-lactic acid in people of color, 451
- Sorafenib**
- annular leukocytoclastic vasculitis associated with (CR), 697
- psoriasiform eruption induced by, in patient with metastatic thyroid carcinoma (CR), 169
- Soy**, cosmeceuticals in clinical practice, s62 (May)
- Spirolactone**
- spironolactone pills versus minoxidil lotion in female pattern hair loss (CTR), 577
- in treatment of acne (NVR), 546
- Squamous cell carcinoma (SCC)**
- dasatinib for unresectable or metastatic SCC (CTR), 285
- dasatinib for unresectable or metastatic SCC or RAI stage 0–1 chronic lymphocytic leukemia (CTR), 883
- efficacy of PDT for recurrent SCC and BCC, 122
- electrodesiccation and curettage versus excision for, 773
- electronic brachytherapy for non-melanoma skin cancer (CTR), 1033
- erlotinib and radiotherapy for cutaneous SCC (CTR), 82, 285
- erlotinib in women with SCC of vulva (CTR), 1289
- erlotinib prior to surgery or radiation in patients with (CTR), 883, 1289
- flexible scalpel for minimally invasive and minimally scarring surgery for large scalp tumors, 1268
- multi-wavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented skin lesions (CTR), 1033
- PDT to treat actinic damage in patients with SCC of lip (CTR), 82, 1289
- ZD1839 for recurrent or metastatic SCC of skin (CTR), 883
- SRT2104**, clinical activity, safety, and tolerability in subjects with psoriasis (CTR), 1446
- Staphylococcus aureus infection**
- methicillin-resistant (MRSA)
- new antibiotics for (NVR), 77
- oregano-based ointment with antimicrobial activity against, 377
- retapamulin versus linezolid in treatment of SITL and impetigo due to (CTR), 86, 1538
- Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282
- using off-patent antibiotics for (CTR), 1538
- retapamulin and antimicrobial resistance of, 1198
- Statins in skin**, 921
- Stelara**. See Ustekinumab

**Stem cell transplantation**

alemtuzumab followed by peripheral stem cell transplantation in advanced mycosis fungoides/Sézary syndrome (CTR), 888  
 combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289  
 hematopoietic stem cell support in patients with autoimmune bullous skin disorders (CTR), 1289  
 safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289  
 Soligenix study of orBec® for prevention of GVHD after (PP), 1033

**Steroid sulfatase gene deletion**, in Egyptian males with X-linked ichthyosis, 1192

**Stevens-Johnson syndrome**

(NVR), 1545  
 bupropion-induced, with acute psoriatic exacerbation (CR), 1010

fluconazole-associated, 1272

**Stress**, relaxation strategies for patients during dermatologic surgery, 795

**Stretch marks**

first fractional laser FDA cleared for (PP), 418  
 Mederma® for (PP), 418

**Sulfonamides**, safety of dapsone in patients with allergies to, 532

**Sulfur**, multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in treatment of inflammatory facial dermatoses (BC), 234

**Sunburn**, iron overload and (NVR), 719

**Sunscreens**

dermal effects of nanoparticles, 475  
 Iredale Mineral Cosmetics receives Seal of Recommendation from Skin Cancer Foundation, 572  
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11  
 update: controversies, what's safe, what's next (NVR), 1446

**T****T cells**

CTLA4-induced splenomegaly and literature review of autoimmune complications of therapy (CR), 1432

and dendritic cells in immunotherapy, 1383  
 role of complement in dendritic cell control of subsets of (editorial), 1364

TH17 in regression of metastatic melanoma to topical diphencyprone, 1368

**T4N5 liposome lotion**, reduced number of AK with, 1519

**Tacrolimus**

cost-effectiveness versus pimecrolimus cream for atopic dermatitis, 372

drug-associated acne and acneiform eruptions, 627

for pruritus in atopic dermatitis, 488

in treatment of morphea, 1213

**Tamiflu®**. See Oseltamivir

**Tanning beds**, FDA recommendations for use (PP), 874

**Tarceva®**. See Erlotinib

**Tattoo treatment**

alexandrite laser with two Nd:YAG laser handpieces pumped by alexandrite treatment beam for, 1333

"tattoo blow-out" pigment spread treated with QS-Nd:YAG laser (CR), 1429

**Taxotere**, eruption secondary to (CR), 1534

**Tazarotene**

safety and efficacy of tazarotene cream and adapalene gel in facial acne vulgaris, 549

safety and efficacy of tazarotene foam in subjects with facial acne (CTR), 187, 425, 1446  
 topical, rapid improvement in digital ischemia and acral contracture in colloidion baby treated with (CR), 713

**TDT 067**, in onychomycosis (CTR), 1538

**Tea polyphenols**, oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

**Telavancin** (NVR), 76

**Temozolomide**, urticarial hypersensitivity reaction caused by (CR), 1142

TempASSURE device (PP), 418

**Teplizumab (MGA031)**, safety in subjects with moderate or more severe psoriasis (CTR), 82, 187, 425, 577

**Terbinafine gel**, efficacy and safety of iontophoretic application in onychomycosis (CTR), 577, 1155

**Tetraethylthiuram disulfide**, drug-associated acne and acneiform eruptions, 627

**Thalidomide**

and analogues for immunomodulation of inflammatory and neoplastic disorders, 814

effect on nitric oxide production in RAW 264.7 cells, 330

**Thymosin beta-4**, effect on wound healing in epidermolysis bullosa (CTR), 727

**Tigecycline**

(NVR), 76

increased mortality risk linked to (PP), 1455

**Tinea pedis**, Ertaczo® relieves itching (PP), 80

**Tissue expanders**, utilization in closure of large Mohs surgical defect (CR), 149

**Tissue fillers**

attaining predictable aesthetic results with, 458  
 Belotero dermal filler close to FDA approval (PP), 1455

calcium hydroxyapatite in nonsurgical aesthetic rejuvenation, 446

correction of atrophic acne scars with Artefill®, 1062

effect of lidocaine when mixed with large gel particle hyaluronic acid filler on tolerability and longevity, 1097

Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538

Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538

for facial shaping, s129 (August)

FDA approves Juvéderm® XC with lidocaine (PP), 418

histopathologic identification of, 1072

hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for aesthetic rejuvenation therapy, 1135

injection techniques for revolumization of perioral region with hyaluronic acid, 367

lip tenting technique, 559

localization and histology of injected hyaluronic acid in excised nasolabial fold tissue (CR), 399

minimally invasive techniques for periorbital rejuvenation, s118 (August)

monophasic, cohesive-polydensified-matrix crosslinking-technology-based HA filler for facial lipatrophy in HIV-infected patients (CR), 690

pain with Radiesse® with lidocaine for nasolabial folds (CTR), 577

Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187

tolerability and efficacy of novel formulation of hyaluronic acid in treatment of melasma, 215

treatment of facial atrophic scars with Esthélic, 1507

treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538

use of injectable poly-L-lactic acid in people of color, 451

**Titanium dioxide**, sunscreen update: controversies, what's safe, what's next (NVR), 1446

**Topically dissolved oxygen (TDO)**, to ameliorate signs of photodamage (CTR), 187, 425

**Torezolid phosphate**, phase 3 study of (PP), 1160

**Toxic epidermal necrolysis**

(NVR), 1545

due to cardiac catheterization dye (CR), 837

**TR-701**, for bacterial skin infections (CTR), 1538

**Training**, identifying the right dermatologic surgery fellowship for you (RR), 421

**Transplant recipients**, ALA-PDT versus vehicle PDT for AK and reduction of new non-melanoma skin cancer in solid organ transplant recipients (CTR), 82

**Travatan**. See Travoprost

**Travoprost**, effects of Xalatan, Travatan and Lumigan of skin pigmentation near eye (CTR), 1289

**Tretinoin**

acne relapse rate of oral minocycline versus oral minocycline combined with topical tretinoin, followed by topical tretinoin alone (CTR), 577, 727

antimicrobial efficacy of benzoyl peroxide/clindamycin phosphate gel versus clindamycin phosphate/tretinoin gel for acne vulgaris, 131

Atralin gel for rosacea (CTR), 1033, 1538

irritation potential of tretinoin gel microsphere pump versus adapalene plus benzoyl peroxide gel, 998

morning/morning regimen of tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for acne, 805

optimizing acne therapy with unique vehicles, s53 (May)

safety and efficacy of clindamycin and tretinoin gel for rosacea (CTR), 187, 285, 425, 1033, 1538

topical tretinoin gel and acne in preadolescents (PP), 1033

treating photodamage of décolletage area with novel copper zinc malonate complex plus hydroquinone and, 220

**Triamcinolone**, efficacy of triamcinolone 0.1% cream occluded with hydrogel patch versus triamcinolone 0.1% cream without occlusion for eczema (CTR), 883

**Trichloroacetic acid**, utilizing combination or sequential treatment with 5-fluorouracil cream and destructive treatments (CR), 864

**Triclosan**, FDA reviewing safety of antibacterial soap ingredient (PP), 874

**Trimethoprim-sulfamethoxazole**, using off-patent antibiotics for MRSA (CTR), 1538

**Tumor necrosis factor - effect of thalidomide on nitric oxide production in RAW 264.7 cells**, 330

**Tygacil**. See Tigecycline

(CR), 711  
 prompt biological therapy speeds diabetic foot ulcer healing (PP), 1455  
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96

**Ultrasonography**  
 FDA approves Ulthera's ultrasound product (PP), 282  
 high resolution ultrasound helps in diagnosis of blue skin lesions (PP), 1160

**Ultravate® ointment.** See Halobetasol propionate ointment

**Ultraviolet (UV) radiation exposure**  
 and immunosuppression in cutaneous melanoma (CTR), 1289  
 PEG-interferon alfa-2b and UV light therapy in mycosis fungoides/Sézary syndrome (CTR), 888  
 proposed indoor tanning tax (PP), 282  
 role of phototherapy in cutaneous T-cell lymphoma, 764  
 maintenance phototherapy, 800  
 usefulness of narrowband UVB as monotherapy for chronic plaque psoriasis, 989

**Urticaria**  
 chronic  
 etanercept for (CTR), 1155  
 hydroxychloroquine efficacy in (CTR), 1155  
 safety and efficacy of abatacept after inadequate response to antihistamine therapy (CTR), 82, 1155  
 second-generation antihistamines for, 503  
 hypersensitivity reaction caused by temozolomide (CR), 1142  
 in pregnancy (NVR), 1297

**Ustekinumab**  
 effects on primate/human antigen-recall and humoral immune response functions, 677  
 versus etanercept for psoriasis (PP), 572  
 how and when to use biologics in psoriasis, s106 (August)  
 for psoriasis and psoriatic arthritis, 947  
 safety and efficacy in psoriatic arthritis patients who have prior exposure to anti-TNF agents (CTR), 1155  
 use in pediatric psoriasis, 975

**V**

**Vaccines**  
 FDA approves new indications for HPV vaccine (PP), 80  
 Sanofi Pasteur and Syntiron development of MRSA vaccine (PP), 282  
 vaccine therapy in stage IV cutaneous melanoma (CTR), 1289

**Valacyclovir**  
 versus EPB-348 for herpes zoster (CTR), 1033  
 versus FV-100 for herpes zoster (CTR), 1033  
 Mylan receives approval for generic (PP), 1033

**Valproate,** drug-associated acne and acneiform eruptions, 627

**Vasculature**  
 annular leukocytoclastic vasculitis associated with sorafenib (CR), 697  
 combination stem cell therapy for treatment of severe leg ischemia (CTR), 1289  
 FDA approves polidocanol for small varicose veins (PP), 723  
 iron overload and chronic venous disease (NVR), 719  
 nanotechnology as topical therapeutic strategy for vascular dysfunction (RR), 574  
 safety of adult stem cells to treat patients with severe leg artery disease (CTR), 1289

**VB-201,** for psoriasis (CTR), 1033, 1446

**Vectibix®.** See Panitumumab

**VECTRA M3 facial imaging system (PP),** 418

**Venous insufficiency ulcers,** FDA clearance of V.A.C. therapy for (PP), 1160

**Verapamil,** medical and surgical management of keloids, 1249

**Vericose veins,** FDA approval of polidocanol for sclerotherapy (NVR), 871

**Vibativ.** See Telavancin

**Vibrio vulnificus infection,** drug therapy for, 341

**Vincristine,** for infantile hemangiomas (NVR), 176

**Vitamin A,** in treatment of morphea, 1213

**Vitamin B6,** drug-associated acne and acneiform eruptions, 627

**Vitamin B12**  
 drug-associated acne and acneiform eruptions, 627  
 topical, for childhood atopic dermatitis (CTR), 1155, 1446

**Vitamin C**  
 cosmeceuticals in clinical practice, s62 (May)  
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

**Vitamin D analogues,** in treatment of morphea, 1213

**Vitamin E**  
 cosmeceuticals in clinical practice, s62 (May)  
 hydrocortisone, silicone and vitamin E lotion for keloids and hypertrophic scars, 514  
 oxidative damage, skin aging, antioxidants and a novel antioxidant rating system, 11

**Vitiligo,** failure of botulinum toxin treatment for, 1092

**Vivité Skin Care System,** controlled multi-center study evaluating the efficacy for photoaging of face, eye and mouth, 22

**Voriconazole,** in X-linked chronic granulomatous disease, photosensitivity/photoaging induced by (CR), 562

**Vulva,** erlotinib in women with SCC of (CTR), 1289

**W**

**Warfarin-induced skin necrosis (CR),** 859

**Warts,** FDA approves new indications for HPV vaccine (PP), 80

**White petrolatum,** drug-associated acne and acneiform eruptions, 627

**Wong type dermatomyositis,** 1475

**Wound dressings,** exSALT SD7™ compared to Xeroform® petrolatum dressing for management of partial thickness donor sites (CTR), 727

**Wound healing**  
 assessment of mechanisms of improved wound healing (CTR), 727  
 beta-blocker for chronic wound healing (CTR), 727  
 comparative efficacy and safety of topical hemostatic powder and sterile compressed foam sponge in second intention healing after Mohs micrographic surgery, 137  
 effect of thymosin beta-4 on wound healing in epidermolysis bullosa (CTR), 727  
 efficacy of hexapeptide-7 on menopausal skin, 49  
 isotretinoin-induced effects of mast cells on, 1207  
 rapid wound re-epithelialization and BCC clearance after Mohs micrographic surgery with postoperative PDT (CR), 143  
 rapid wound re-epithelialization and BCC clearance after Mohs surgery with postoperative PDT (RR), 878  
 safety of topical doxycycline gel for adult diabetic lower extremity ulcers (CTR), 96  
 vertical undermining for closure of partial thickness surgical defects, 674

**Wrinkles**  
 comparison of RevLite Electro-optic Q-switched neodymium-doped yttrium aluminium garnet laser to a fractionated laser system (CTR), 82, 187, 425, 1033, 1155, 1289  
 controlled multi-center study evaluating the efficacy of Vivité Skin Care for photoaging of face, eye and mouth, 22  
 Emervel Classic Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 Emervel Deep Lidocaine versus Juvederm Ultra Plus for facial wrinkles and folds (CTR), 1538  
 FDA approval of eMatrix device for (PP), 572  
 novel sonic infusion system for periorbital rhytides, 1121  
 prospective study of improvement in periorbital wrinkles and eyebrow elevation with novel fractional CO2 laser—the fractional eyelift, 16  
 Restylane and Perlane in correction of peri-oral wrinkles (CTR), 187  
 treatment of forehead/glabellar rhytide complex with combination botulinum toxin A and hyaluronic acid versus botulinum toxin injection alone (CTR), 1538

**X**

**Xalatan.** See Latanoprost

**Xeomin®.** See Incobotulinumtoxin A

**Xeroform® petrolatum dressing,** compared to exSALT SD7™ for management of partial thickness donor sites (CTR), 727

**X-linked chronic granulomatous disease,** voriconazole-induced photosensitivity/photoaging in (CR), 562

**X-linked ichthyosis,** steroid sulfatase gene deletion in Egyptian males with, 1192

**Xyzal.** See Levocetirizine

**Z**

**Zanolimumab,** to treat mycosis fungoides/Sézary syndrome (CTR), 888

**ZD1839.** See Gefitinib

**Zeftera.** See Ceftriaxone

**Zerona,** FDA-approved for body slimming (PP), 1455

**Zinc oxide,** sunscreen update: controversies, what's safe, what's next (NVR), 1446

**Zyclara™.** See Imiquimod cream



